{"meta":{"query_hash":"458495b2c95b","filters":{"venue":"Targeted Oncology"},"cohort_total":57,"direct_labels_cover":0,"predictions_cover":57,"exported":57,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/458495b2c95b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Targeted+Oncology"},"results":[{"id":"W1627803359","doi":"10.1007/s11523-015-0386-5","title":"Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN)","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cancer research; Sulforaphane; Protein kinase B; PI3K/AKT/mTOR pathway; Clonogenic assay; Apoptosis; Bladder cancer; Epithelial–mesenchymal transition; Survivin; Pharmacology; Cancer; Internal medicine; Chemistry; Metastasis; Biochemistry","score_opus":0.013589086711456975,"score_gpt":0.25220228280851553,"score_spread":0.23861319609705856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1627803359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926058,0.0019670741,0.0030468774,0.00017331833,0.000042110933,0.000055310556,0.00015177838,0.00007562429,0.0018820813],"genre_scores_gemma":[0.99704045,0.000710911,0.001401566,0.00002310171,0.000009445707,0.000024330373,0.00006794582,0.0000037949108,0.0007184518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993265,0.000009051362,0.000004180881,0.000012955516,0.000016808972,0.00002432813],"domain_scores_gemma":[0.9999728,0.000004186072,0.00000803957,0.000003492368,0.0000024965518,0.000009044271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010261836,0.00027477907,0.0002788701,0.00017115097,0.00013586742,0.00017864734,0.00019436433,0.00014704344,0.00077234535],"category_scores_gemma":[0.0000615872,0.00008158372,0.00017926574,0.00016103506,0.00019679904,0.00016727159,0.0001480169,0.0003725883,0.00008161142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008457323,0.00015575154,0.0004120797,0.00006316344,0.000017107486,0.000054944587,0.000016552656,0.00039016502,0.9846821,0.00028807882,0.00015583697,0.012918496],"study_design_scores_gemma":[0.0002190065,0.0033656147,0.0037415766,0.000007975355,0.00008605913,0.00035363692,0.000033626726,0.0024661385,0.9852372,0.00010132017,0.0043779314,0.0000099180725],"about_ca_topic_score_codex":0.0009741575,"about_ca_topic_score_gemma":0.0033632994,"teacher_disagreement_score":0.0009741575,"about_ca_system_score_codex":0.00023845643,"about_ca_system_score_gemma":0.0004836489,"threshold_uncertainty_score":0.0025838017},"labels":[],"label_agreement":null},{"id":"W1967370517","doi":"10.1007/s11523-014-0356-3","title":"Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Neutrophilia; Lymphocytopenia; Nephrectomy; Sunitinib; Oncology; Univariate analysis; Gastroenterology; Neutrophil to lymphocyte ratio; Targeted therapy; Multivariate analysis; Cancer; Lymphocyte; Kidney","score_opus":0.013345270174694153,"score_gpt":0.24004238192754693,"score_spread":0.2266971117528528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967370517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983777,0.0008143156,0.000090455855,0.00007104446,0.000014328571,0.000003955749,0.00010324494,0.000003682314,0.000521242],"genre_scores_gemma":[0.99955875,0.00012320484,0.00003987026,0.000028864835,0.000025488802,0.0000029307719,0.0001285514,0.0000011010475,0.00009125471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998388,0.000036862424,0.000020242755,0.000027437647,0.000026446309,0.00005013987],"domain_scores_gemma":[0.99911135,0.00020649437,0.00037191715,0.00003335464,0.00007808077,0.00019868618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003151231,0.00018017826,0.00041014454,0.0004222868,0.000311819,0.0005020576,0.00020730533,0.00032195944,0.0007934429],"category_scores_gemma":[0.0012974463,0.0000821856,0.00033446125,0.00062867586,0.00024769484,0.0003383555,0.00022966367,0.00046180325,0.0001043854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006305893,0.000028493901,0.99511284,0.000010242768,0.000044466895,0.00016492805,0.00002630399,0.00009691913,0.00070918066,0.000019442828,0.00007688674,0.0030796505],"study_design_scores_gemma":[0.0000238944,0.0004341672,0.9969086,0.0000085907695,0.000116927025,0.0009582892,0.00013006279,0.00052977627,0.00035023675,0.00008290364,0.00045055556,0.000006091117],"about_ca_topic_score_codex":0.0006682278,"about_ca_topic_score_gemma":0.0010844573,"teacher_disagreement_score":0.0007934429,"about_ca_system_score_codex":0.00028590066,"about_ca_system_score_gemma":0.00032516013,"threshold_uncertainty_score":0.0026543736},"labels":[],"label_agreement":null},{"id":"W1973375841","doi":"10.1007/s11523-009-0120-2","title":"Nuclear imaging of molecular processes in cancer","year":2009,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Molecular imaging; Medicine; Positron emission tomography; Nuclear medicine; Nuclear imaging; Pet imaging; Medical physics; Cancer; Internal medicine; In vivo; Biology; Biotechnology","score_opus":0.04336537521571856,"score_gpt":0.42497326225833704,"score_spread":0.3816078870426185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973375841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000092575196,0.99804854,0.00037130297,0.00016392165,0.00017007126,0.0000060924376,0.0000085663105,0.000008482916,0.001130476],"genre_scores_gemma":[0.0006471429,0.99772984,0.00042487643,0.00016555967,0.00016440198,0.000007018181,0.000015730513,0.000002249216,0.0008431541],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997795,0.000047554207,0.000025708308,0.000038094047,0.00008546413,0.000023606844],"domain_scores_gemma":[0.99939203,0.00034285235,0.00007609979,0.000019018402,0.00013768359,0.000032219792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009625449,0.0014593023,0.0016462345,0.002919959,0.00034009278,0.0011292079,0.0012286098,0.0017069206,0.0032679415],"category_scores_gemma":[0.0010891551,0.00057097326,0.00047245887,0.0028889258,0.0012098593,0.00195477,0.0009071105,0.0018817345,0.0026128166],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012144673,0.000081332866,0.0001408694,0.015339781,0.00007757587,0.00039104332,0.000081407976,0.00059196685,0.0056827026,0.0043728603,0.03361234,0.9395066],"study_design_scores_gemma":[0.000025138483,0.00009051187,0.00034521273,0.0021952142,0.000104198996,0.0023972674,0.000053731455,0.00016661483,0.0022024435,0.001511209,0.9908805,0.000027896123],"about_ca_topic_score_codex":0.002006159,"about_ca_topic_score_gemma":0.0033930873,"teacher_disagreement_score":0.0032679415,"about_ca_system_score_codex":0.0010153339,"about_ca_system_score_gemma":0.0013912215,"threshold_uncertainty_score":0.010932386},"labels":[],"label_agreement":null},{"id":"W1980810683","doi":"10.1007/s11523-007-0042-9","title":"Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study","year":2007,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ste. Anne's Hospital","funders":"National Cancer Institute; World Health Organization","keywords":"Docetaxel; Medicine; Gefitinib; Internal medicine; Lung cancer; Chemotherapy; Oncology; Combination therapy; Adverse effect; Rash; Cancer; Epidermal growth factor receptor","score_opus":0.013741353526704404,"score_gpt":0.3733654310320024,"score_spread":0.359624077505298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980810683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873152,0.004733432,0.00072964595,0.0006918164,0.0005958992,0.0027002196,0.0013876176,0.00014884131,0.0016973573],"genre_scores_gemma":[0.9849583,0.0036870614,0.0014903846,0.0011353304,0.0005520124,0.003046815,0.001998436,0.00007139807,0.0030603197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988457,0.00044272238,0.000050966046,0.0002810384,0.000081932434,0.00029764188],"domain_scores_gemma":[0.9988582,0.00019914322,0.00021018756,0.000107903055,0.000060019134,0.00056454964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024237207,0.0029355336,0.0069663124,0.0008864314,0.00081516744,0.0019638753,0.0014889743,0.0024150133,0.006063129],"category_scores_gemma":[0.0012243994,0.0012397465,0.0037113093,0.0008674159,0.0019276299,0.0022987996,0.000607156,0.0055555203,0.0013163196],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95104134,0.017293712,0.0014052468,0.00051430555,0.0020083683,0.00005956375,0.00007610891,0.0010929856,0.0034485434,0.00012587417,0.0014672279,0.02146664],"study_design_scores_gemma":[0.8570209,0.13751265,0.0024783304,0.000025227691,0.00089188793,0.000065787375,0.000026271355,0.00042497402,0.00058301864,0.000085100524,0.00086020934,0.000025599811],"about_ca_topic_score_codex":0.0029288337,"about_ca_topic_score_gemma":0.0072935885,"teacher_disagreement_score":0.0069663124,"about_ca_system_score_codex":0.0023014073,"about_ca_system_score_gemma":0.0022398385,"threshold_uncertainty_score":0.020283222},"labels":[],"label_agreement":null},{"id":"W1999755104","doi":"10.1007/s11523-014-0308-y","title":"Transforming growth factor-beta and its implication in the malignancy of gliomas","year":2014,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Glioma; Medicine; Cancer research; Malignancy; Transforming growth factor beta; Angiogenesis; Cytokine; Growth factor; Transforming growth factor; Pathology; Hepatocyte growth factor; Immunology; Internal medicine; Receptor","score_opus":0.029328501467559887,"score_gpt":0.33678045228020836,"score_spread":0.3074519508126485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999755104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010016159,0.9990308,0.000098825825,0.00021828452,0.00011165311,0.000001710339,0.000011524763,0.0000039141164,0.00042312877],"genre_scores_gemma":[0.0007552426,0.99853754,0.00011753824,0.00012000722,0.00014731861,0.0000025601416,0.000017395188,7.6314114e-7,0.00030153763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998958,0.000013270305,0.000013888578,0.000016305188,0.000046601926,0.000014067041],"domain_scores_gemma":[0.9998171,0.0000756811,0.000034566983,0.000005111517,0.00004575505,0.00002183704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041248873,0.0006124746,0.0009662082,0.0013574486,0.0001681755,0.00088401703,0.00061965705,0.00081867864,0.0018768733],"category_scores_gemma":[0.0005051849,0.00019991184,0.00029098586,0.0014966291,0.00040653453,0.0007316557,0.00048522773,0.0015454656,0.001096924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105919244,0.000047275287,0.00020798628,0.008929552,0.00007693232,0.00031455827,0.00003800535,0.0004088338,0.0025586886,0.003880707,0.027019663,0.95641184],"study_design_scores_gemma":[0.0000265405,0.000063434985,0.0008766108,0.001760724,0.00014534392,0.001701194,0.00004757658,0.000116578914,0.0009788335,0.0023955496,0.99186784,0.00001987403],"about_ca_topic_score_codex":0.0010499316,"about_ca_topic_score_gemma":0.002073409,"teacher_disagreement_score":0.0018768733,"about_ca_system_score_codex":0.0005658878,"about_ca_system_score_gemma":0.0009958622,"threshold_uncertainty_score":0.0062787533},"labels":[],"label_agreement":null},{"id":"W2021963511","doi":"10.1007/s11523-008-0093-6","title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies","year":2008,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Parks and Wilderness Society","funders":"","keywords":"Medicine; Cetuximab; Epidermal growth factor receptor; EGFR inhibitors; Tyrosine kinase; Lung cancer; Cancer; Colorectal cancer; Cancer research; Drug resistance; Gefitinib; Erlotinib; Signal transduction; Targeted therapy; Receptor tyrosine kinase; Bioinformatics; Oncology; Internal medicine; Receptor; Biology","score_opus":0.013520744220156556,"score_gpt":0.3217577086328896,"score_spread":0.30823696441273307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021963511","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3183106,0.5243379,0.062493477,0.058191277,0.00061428087,0.00066290627,0.00062781264,0.00082470605,0.033937044],"genre_scores_gemma":[0.8421857,0.13177747,0.017023928,0.0051369118,0.0009727803,0.00032001396,0.00031214743,0.00006851584,0.0022026931],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869305,0.0006611245,0.000108560096,0.00014982108,0.00030689323,0.00008054939],"domain_scores_gemma":[0.9979735,0.0012703092,0.00039202964,0.00008577458,0.0001738829,0.00010444617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044931746,0.000585912,0.001852943,0.0011318232,0.00022956535,0.002152071,0.0010404473,0.0013011198,0.0015561662],"category_scores_gemma":[0.0055106715,0.0002832977,0.0005128292,0.00078398205,0.00074193603,0.0016223011,0.0004536672,0.001524033,0.00045614433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019943796,0.0008295524,0.0741641,0.0010658299,0.00035474624,0.0017363116,0.00034032617,0.010706245,0.026638055,0.025338238,0.009369139,0.8474631],"study_design_scores_gemma":[0.0022876288,0.018662613,0.27617604,0.00219717,0.0028045978,0.04944619,0.0024008336,0.08969069,0.10952166,0.15733483,0.2888554,0.0006224121],"about_ca_topic_score_codex":0.00020590705,"about_ca_topic_score_gemma":0.0002794562,"teacher_disagreement_score":0.0044931746,"about_ca_system_score_codex":0.0012264748,"about_ca_system_score_gemma":0.0007607391,"threshold_uncertainty_score":0.023762465},"labels":[],"label_agreement":null},{"id":"W2037096531","doi":"10.1007/s11523-012-0252-7","title":"The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; London Health Sciences Centre; University of Alberta; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Targeted therapy; VEGF receptors; Internal medicine; Second-line therapy; Cancer; Chemotherapy","score_opus":0.07733604392423403,"score_gpt":0.3777414729966405,"score_spread":0.30040542907240647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037096531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945861,0.0016402055,0.00024419618,0.00030077118,0.00004071151,0.000010254828,0.0003598881,0.000009193456,0.0028086083],"genre_scores_gemma":[0.99900997,0.00017251186,0.00003289004,0.00006909802,0.000045103254,0.0000044826297,0.000390324,0.0000029282746,0.0002726029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995285,0.00011318042,0.000047218247,0.00007738132,0.000070661605,0.00016311633],"domain_scores_gemma":[0.9972875,0.0008248062,0.0009685339,0.00010311234,0.00021416535,0.0006018865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008194342,0.0001729379,0.00047169588,0.00040129013,0.00027490643,0.0007790988,0.00025229593,0.00046361735,0.002198781],"category_scores_gemma":[0.00345226,0.00007870582,0.00077970634,0.00053779926,0.00026132682,0.0005038336,0.00038874353,0.00093669683,0.00026738923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00222115,0.000099894954,0.9887372,0.000022640521,0.0002734193,0.00021789243,0.000034775127,0.0003322097,0.00089013495,0.00011901562,0.00035128836,0.0067004804],"study_design_scores_gemma":[0.000044447333,0.0007997839,0.9966757,0.000010673343,0.00016433341,0.0005734884,0.00009593092,0.00063857564,0.000217113,0.00022371905,0.00054588495,0.000010354928],"about_ca_topic_score_codex":0.0011231385,"about_ca_topic_score_gemma":0.0015283587,"teacher_disagreement_score":0.002198781,"about_ca_system_score_codex":0.0005746213,"about_ca_system_score_gemma":0.00052719016,"threshold_uncertainty_score":0.00735569},"labels":[],"label_agreement":null},{"id":"W2061663237","doi":"10.1007/s11523-010-0143-8","title":"Prognostic and predictive biomarkers in renal cell carcinoma","year":2010,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Biomarker; Biomarker discovery; Kidney cancer; Vascular endothelial growth factor; Clear cell renal cell carcinoma; Oncology; Targeted therapy; Cancer; Pathology; Cancer research; Bioinformatics; Internal medicine; VEGF receptors; Proteomics; Biology; Gene","score_opus":0.03238352251163952,"score_gpt":0.3148014887375521,"score_spread":0.2824179662259126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061663237","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010523244,0.9991755,0.0001127059,0.00022900946,0.00010247134,0.000003993253,0.000026059302,0.000004151332,0.00024072513],"genre_scores_gemma":[0.0011808486,0.9979074,0.00022062942,0.00024292046,0.00017530443,0.000006236462,0.000053649575,0.0000010507663,0.0002120753],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962914,0.00007507309,0.00007470457,0.000064464126,0.00012928699,0.00002730296],"domain_scores_gemma":[0.9989428,0.0005601295,0.000225625,0.000024422452,0.00020984963,0.00003719258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001499425,0.0011861636,0.002973292,0.002364832,0.00023438262,0.0014219608,0.0012130378,0.0010314347,0.0015426083],"category_scores_gemma":[0.0023501185,0.00043990143,0.0010363054,0.003046957,0.00057757733,0.001482071,0.0006474347,0.0020049412,0.0007683391],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015585862,0.000068532456,0.0010328023,0.019221254,0.00040724216,0.00014184973,0.000034156714,0.000522587,0.00058564066,0.001705018,0.024172217,0.9519528],"study_design_scores_gemma":[0.00017580276,0.0004022809,0.0078066634,0.019438904,0.003365725,0.0024895598,0.00015861206,0.0008630346,0.0013803551,0.0048108404,0.9590099,0.00009845479],"about_ca_topic_score_codex":0.0019301185,"about_ca_topic_score_gemma":0.0030722793,"teacher_disagreement_score":0.002973292,"about_ca_system_score_codex":0.0009511535,"about_ca_system_score_gemma":0.0018828963,"threshold_uncertainty_score":0.007929862},"labels":[],"label_agreement":null},{"id":"W2076911447","doi":"10.1007/s11523-013-0299-0","title":"Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Bayer HealthCare","keywords":"Medicine; Liter; Sorafenib; Placental growth factor; Internal medicine; Vascular endothelial growth factor; Endoglin; VEGF receptors; Angiosarcoma; Gastroenterology; Hepatocellular carcinoma; Pathology; Stem cell; CD34","score_opus":0.04767621424879121,"score_gpt":0.305364035680701,"score_spread":0.25768782143190977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076911447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886024,0.0005053699,0.00011437471,0.00008121341,0.000032878776,0.000045121273,0.00016138788,0.0000074757922,0.00019194056],"genre_scores_gemma":[0.99822253,0.00029331495,0.00023575849,0.0001459929,0.00008771933,0.00006641216,0.0006087265,0.0000050156705,0.00033453054],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99957126,0.00018826709,0.000032030886,0.00008967098,0.000047258738,0.00007138205],"domain_scores_gemma":[0.9987363,0.00037661672,0.00038240146,0.00010043505,0.0000688071,0.0003354332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015025516,0.0008530733,0.0012343839,0.00022106031,0.00030498902,0.0009883619,0.0003274232,0.0005873649,0.0015669962],"category_scores_gemma":[0.0014369272,0.00027912442,0.0012784031,0.00036228547,0.0005321172,0.00069776474,0.00029754173,0.0015902793,0.00025494953],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51755995,0.014910657,0.32932803,0.00060617225,0.007188479,0.0004923953,0.00028977625,0.0022788155,0.04909551,0.00025057961,0.0023153895,0.07568419],"study_design_scores_gemma":[0.088367976,0.2351715,0.65390027,0.00006189727,0.005564035,0.0014721652,0.00029780416,0.003909445,0.0063520162,0.00076841516,0.004007282,0.0001272251],"about_ca_topic_score_codex":0.00023828553,"about_ca_topic_score_gemma":0.00048628275,"teacher_disagreement_score":0.0015669962,"about_ca_system_score_codex":0.00032923554,"about_ca_system_score_gemma":0.00044875662,"threshold_uncertainty_score":0.007946372},"labels":[],"label_agreement":null},{"id":"W2091875870","doi":"10.1007/s11523-013-0271-z","title":"An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Amgen (Canada)","funders":"Amgen","keywords":"Panitumumab; KRAS; Medicine; Internal medicine; Hazard ratio; Oncology; Post-hoc analysis; Colorectal cancer; Randomized controlled trial; Cancer; Confidence interval","score_opus":0.009570761703216482,"score_gpt":0.31502422195572594,"score_spread":0.30545346025250947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091875870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98232365,0.009193742,0.0026357323,0.0006457899,0.00040713805,0.0018578689,0.001176077,0.000099024415,0.0016609664],"genre_scores_gemma":[0.99292976,0.0018364775,0.00193848,0.00054358394,0.00030463663,0.0008643641,0.00076181063,0.0000287101,0.0007920999],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98735666,0.010782559,0.00036721848,0.00061178824,0.0005051321,0.00037653247],"domain_scores_gemma":[0.98270494,0.012272048,0.002774352,0.0010180704,0.00046740792,0.0007631244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018912913,0.0019050237,0.0027919235,0.0007089525,0.00033198777,0.00091708713,0.00083179487,0.0014970938,0.0026604787],"category_scores_gemma":[0.017207123,0.0005388326,0.007626997,0.0005747172,0.0008539241,0.0009356955,0.0006269293,0.0030552724,0.00020599131],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95912665,0.0026561713,0.002843823,0.000974414,0.012751983,0.000074755066,0.000053267173,0.001419181,0.0020693457,0.00016558205,0.000758458,0.017106256],"study_design_scores_gemma":[0.6744896,0.2703497,0.022732344,0.00011050297,0.024012046,0.00016681376,0.000053494583,0.003648339,0.0022617297,0.0004825821,0.0016378495,0.00005495235],"about_ca_topic_score_codex":0.0007895398,"about_ca_topic_score_gemma":0.0017266243,"teacher_disagreement_score":0.018912913,"about_ca_system_score_codex":0.000956827,"about_ca_system_score_gemma":0.0012899068,"threshold_uncertainty_score":0.10002226},"labels":[],"label_agreement":null},{"id":"W2201788027","doi":"10.1007/s11523-015-0396-3","title":"Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Prostate; Adenocarcinoma; Prostate adenocarcinoma; Prostatic adenocarcinoma; Pathology; Lymphocyte; Castration; Prostate cancer; Oncology; Internal medicine; Cancer","score_opus":0.03854617420081482,"score_gpt":0.3205983842461482,"score_spread":0.28205221004533343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2201788027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988674,0.00025225966,0.0001522636,0.0000065791764,0.000002053649,0.000010648071,0.00019878491,0.000005029989,0.00050507626],"genre_scores_gemma":[0.99888355,0.00012593372,0.0001459382,0.00001199485,0.0000052637824,0.000011838701,0.00036659776,0.0000034389655,0.0004455064],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99975973,0.000059986112,0.000016133961,0.0000375751,0.00007105398,0.000055628123],"domain_scores_gemma":[0.9995154,0.00020717726,0.000072484814,0.000049575472,0.00006398129,0.000091396636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004754415,0.00017956736,0.00028318565,0.000700828,0.00021855839,0.0004486046,0.00017278627,0.00023602821,0.0013753689],"category_scores_gemma":[0.0006107381,0.00012601893,0.0002567182,0.0003447411,0.00026804063,0.00023927266,0.00026996285,0.0003651163,0.00022761774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010621182,0.00047868871,0.15600097,0.00019681013,0.00015606498,0.00049661717,0.0003879078,0.0010930736,0.8154245,0.00017077225,0.00015822102,0.014815078],"study_design_scores_gemma":[0.000057421046,0.0058628703,0.87800395,0.000008952692,0.00017076949,0.0018887783,0.00077872403,0.0015422936,0.110047854,0.00009299482,0.0015298753,0.000015528858],"about_ca_topic_score_codex":0.00082015165,"about_ca_topic_score_gemma":0.0009496273,"teacher_disagreement_score":0.0013753689,"about_ca_system_score_codex":0.00018759553,"about_ca_system_score_gemma":0.00014213556,"threshold_uncertainty_score":0.004601121},"labels":[],"label_agreement":null},{"id":"W2516587078","doi":"10.1007/s11523-016-0448-3","title":"Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model","year":2016,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Temsirolimus; Clusterin; Medicine; Renal cell carcinoma; Pharmacology; Cancer research; Apoptosis; Downregulation and upregulation; PI3K/AKT/mTOR pathway; Internal medicine; Biology; Discovery and development of mTOR inhibitors","score_opus":0.02798368675883016,"score_gpt":0.3393615595728084,"score_spread":0.3113778728139782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516587078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806887,0.00047252647,0.00048059036,0.000086876775,0.000038692848,0.000031012394,0.00016222763,0.00003823601,0.00062091585],"genre_scores_gemma":[0.9969139,0.0004359746,0.0009237107,0.000025426352,0.000008954717,0.000042820207,0.00030301057,0.000008767617,0.0013373885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998568,0.000029168557,0.000011556644,0.000027053433,0.000028945704,0.000046428617],"domain_scores_gemma":[0.99993014,0.000014233457,0.000013083095,0.000008281962,0.0000088077995,0.000025420262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002734199,0.0003281588,0.0004742334,0.00020066905,0.00017953807,0.00020517546,0.0002576598,0.00034784933,0.00090256444],"category_scores_gemma":[0.00010321042,0.00011813213,0.00033679963,0.00024902684,0.00035703377,0.00027161336,0.00012807974,0.0009085654,0.00016075232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022801924,0.00052491,0.0001776317,0.000078830795,0.000023675326,0.00004015807,0.000045711044,0.00043669896,0.9930976,0.00015513581,0.0001640789,0.00297531],"study_design_scores_gemma":[0.0001747376,0.0033461107,0.0019530996,0.000002695305,0.00004739916,0.000068917245,0.00003293106,0.0018763744,0.9913538,0.00002921353,0.0011067161,0.000007907224],"about_ca_topic_score_codex":0.0016896768,"about_ca_topic_score_gemma":0.0022154388,"teacher_disagreement_score":0.0016896768,"about_ca_system_score_codex":0.00033506157,"about_ca_system_score_gemma":0.0005969421,"threshold_uncertainty_score":0.0033596754},"labels":[],"label_agreement":null},{"id":"W2560844514","doi":"10.1007/s11523-016-0462-5","title":"Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial","year":2016,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Sunitinib; Placebo; Quality of life (healthcare); Neuroendocrine tumors; Internal medicine; Adverse effect; Oncology; Cancer; Pathology; Alternative medicine","score_opus":0.08123099894244132,"score_gpt":0.41849353098849157,"score_spread":0.3372625320460503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560844514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865436,0.009729459,0.00037905236,0.00051883346,0.00021351365,0.00056539965,0.0008380941,0.000052528507,0.0011594777],"genre_scores_gemma":[0.9938905,0.0026278822,0.0005263386,0.00041041538,0.0002282139,0.00076325785,0.0008701815,0.000014850692,0.0006683924],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989035,0.0005751801,0.000091840746,0.0002123299,0.00008857038,0.00012861718],"domain_scores_gemma":[0.9982975,0.0005843675,0.0005891446,0.000120821984,0.000075018004,0.0003331738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002585311,0.0016553411,0.0031794356,0.00036588308,0.00043659212,0.0010223994,0.0008133705,0.0013501863,0.0028201456],"category_scores_gemma":[0.0022822754,0.00033265946,0.0046748263,0.0005307498,0.0012458018,0.0012965371,0.00044404247,0.0037610196,0.00043496356],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94924647,0.0060567223,0.003111745,0.00090185873,0.0043291366,0.00003962636,0.00007317697,0.0010103027,0.002379358,0.00007356265,0.000736504,0.03204152],"study_design_scores_gemma":[0.793008,0.17987347,0.01920446,0.00010849081,0.00430466,0.00011308446,0.000084442705,0.000858655,0.0012011443,0.00032862445,0.0008679716,0.000046850822],"about_ca_topic_score_codex":0.00055999454,"about_ca_topic_score_gemma":0.001030086,"teacher_disagreement_score":0.0031794356,"about_ca_system_score_codex":0.0009912716,"about_ca_system_score_gemma":0.00071053085,"threshold_uncertainty_score":0.01367259},"labels":[],"label_agreement":null},{"id":"W2735753765","doi":"10.1007/s11523-017-0516-3","title":"A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Hôpital Notre-Dame; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Testosterone (patch); Internal medicine; White blood cell; Neutrophil to lymphocyte ratio; Absolute neutrophil count; Prospective cohort study; Proportional hazards model; Gastroenterology; Urology; Complete blood count; Cancer; Lymphocyte; Confidence interval; Oncology; Toxicity; Neutropenia","score_opus":0.014346547148321195,"score_gpt":0.29776721316101623,"score_spread":0.28342066601269505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735753765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865888,0.0109234,0.0006151225,0.0003482725,0.00017336682,0.000011204141,0.00023033835,0.0000529257,0.0010566391],"genre_scores_gemma":[0.9985203,0.0006906591,0.0002513307,0.00005553331,0.0001589037,0.0000028188292,0.000118523385,0.000004160472,0.00019779203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99948573,0.00023443255,0.000046147496,0.000054028045,0.00011372466,0.00006603972],"domain_scores_gemma":[0.9984484,0.00055377453,0.00041943495,0.00007166631,0.0001396032,0.0003671494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012448321,0.00062816613,0.0010814675,0.0010168246,0.00034686053,0.0012007407,0.00040031254,0.00041240972,0.0007554042],"category_scores_gemma":[0.0026088532,0.00022723134,0.00058361015,0.0015005692,0.0003601041,0.00049604254,0.00027105096,0.00071808114,0.00020648232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002921089,0.00016828247,0.9739769,0.00006105183,0.0004389408,0.00020223093,0.000053884833,0.0007001866,0.0022950706,0.000044474513,0.00033772452,0.018800167],"study_design_scores_gemma":[0.00008075395,0.0019989759,0.98868537,0.000034127308,0.0012262407,0.00079861673,0.00022204849,0.0044912943,0.0011937335,0.00026274525,0.00097209634,0.00003393676],"about_ca_topic_score_codex":0.0013021122,"about_ca_topic_score_gemma":0.0026255336,"teacher_disagreement_score":0.0013021122,"about_ca_system_score_codex":0.00028732268,"about_ca_system_score_gemma":0.0007119197,"threshold_uncertainty_score":0.006583333},"labels":[],"label_agreement":null},{"id":"W2742486699","doi":"10.1007/s11523-017-0518-1","title":"Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars","year":2017,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Pfizer","keywords":"Bevacizumab; Biosimilar; Medicine; Colorectal cancer; Oncology; Intensive care medicine; Internal medicine; Cancer; Chemotherapy","score_opus":0.060309267353295185,"score_gpt":0.4066597918623675,"score_spread":0.34635052450907233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742486699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007560202,0.9880927,0.00071025454,0.0075562485,0.00062211097,0.0000055244345,0.00001120875,0.00001480001,0.0022310277],"genre_scores_gemma":[0.008657684,0.98432297,0.0009626306,0.0025571256,0.0020992297,0.000013543625,0.000029871586,0.000009156754,0.001347923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986959,0.0004586864,0.00011750959,0.00014923925,0.0004917942,0.00008693144],"domain_scores_gemma":[0.99788314,0.0010797813,0.00033202485,0.000050391394,0.00043393747,0.0002207352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029728482,0.00048682097,0.00059580524,0.0012013076,0.00036366863,0.0020580452,0.000522128,0.0019012856,0.0018586736],"category_scores_gemma":[0.0038382113,0.00018713069,0.00040922442,0.0012760917,0.0013491574,0.002491899,0.000913287,0.0029514998,0.000997139],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016214249,0.00009284972,0.000525698,0.0033740147,0.000037176513,0.00022422893,0.00019126767,0.000543733,0.003462695,0.026215795,0.03014983,0.93502057],"study_design_scores_gemma":[0.000026469792,0.00042514264,0.00088734896,0.0017097029,0.000043281172,0.0015455162,0.0001202194,0.00039364176,0.0014180465,0.010641986,0.9827597,0.000029023233],"about_ca_topic_score_codex":0.0010616493,"about_ca_topic_score_gemma":0.0015584871,"teacher_disagreement_score":0.0029728482,"about_ca_system_score_codex":0.0013481241,"about_ca_system_score_gemma":0.0013272681,"threshold_uncertainty_score":0.015722096},"labels":[],"label_agreement":null},{"id":"W2743780916","doi":"10.1007/s11523-017-0525-2","title":"A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Ipsen","keywords":"Medicine; Internal medicine; Oncology; Cohort; Clinical endpoint; Cancer; Sorafenib; Nausea; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Phases of clinical research","score_opus":0.03434511081770929,"score_gpt":0.32998758412842844,"score_spread":0.29564247331071913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743780916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987334,0.003301356,0.0024897375,0.0007533475,0.00035929968,0.002844517,0.0012172434,0.0001526581,0.0015478258],"genre_scores_gemma":[0.9849125,0.0027188454,0.0038800896,0.0012189965,0.00015407993,0.0024093941,0.00170259,0.00006477558,0.0029387819],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995436,0.00016661368,0.000015895454,0.00009931335,0.00004994303,0.0001246769],"domain_scores_gemma":[0.999433,0.000081537335,0.00008132138,0.00007846837,0.00005653272,0.0002691868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002126866,0.0013111832,0.0023521371,0.0003587905,0.0004376092,0.0014131247,0.0008972649,0.0012681554,0.0032071976],"category_scores_gemma":[0.0007760722,0.000638417,0.001821881,0.00038494106,0.0013355535,0.0011555166,0.00034258174,0.0037463105,0.00070831197],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6049904,0.074713856,0.005254392,0.0024330092,0.0040399693,0.00039916454,0.0006347492,0.0060201217,0.166898,0.0012618259,0.009622013,0.12373242],"study_design_scores_gemma":[0.43443558,0.53065413,0.007858711,0.00007365006,0.0013655839,0.00046966042,0.00026353664,0.0024399378,0.0126122795,0.0006976856,0.009049976,0.000079302066],"about_ca_topic_score_codex":0.001277559,"about_ca_topic_score_gemma":0.003288072,"teacher_disagreement_score":0.0032071976,"about_ca_system_score_codex":0.001348246,"about_ca_system_score_gemma":0.0018175747,"threshold_uncertainty_score":0.011248112},"labels":[],"label_agreement":null},{"id":"W2765084883","doi":"10.1007/s11523-017-0530-5","title":"A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Plexxikon; Symphogen; Genentech; Celgene; Sanofi; Ipsen; Chugai Pharmaceutical; Sirtex Medical; Pfizer; Eli Lilly and Company","keywords":"Medicine; Irinotecan; Tolerability; Clinical endpoint; Internal medicine; KRAS; Colorectal cancer; Pharmacokinetics; Pharmacology; Phases of clinical research; Combination therapy; Endometrial cancer; Oncology; Cancer; Urology; Toxicity; Adverse effect; Clinical trial","score_opus":0.03309205630219511,"score_gpt":0.3685072594238245,"score_spread":0.3354152031216294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765084883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050844,0.0009690679,0.0012124317,0.00037414933,0.00012850983,0.004281206,0.0008603957,0.00012801647,0.0015377986],"genre_scores_gemma":[0.98000276,0.0012456459,0.0049882154,0.0008786224,0.00022408405,0.0059074527,0.0026995176,0.000049661365,0.0040040617],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990588,0.00042912317,0.000051148476,0.00017754268,0.00010772913,0.00017572175],"domain_scores_gemma":[0.9987588,0.00014859792,0.00027418375,0.0001519581,0.00006735188,0.0005990266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034910399,0.0023783105,0.0020515742,0.0010455496,0.000532765,0.0011434092,0.0017304898,0.001456052,0.0043942407],"category_scores_gemma":[0.0012216769,0.0011342252,0.0020148647,0.00063739927,0.0012828307,0.0014937444,0.00071047974,0.0043900954,0.0010714506],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71017414,0.15966685,0.0033230698,0.0007116578,0.0013472108,0.00017751058,0.0002480684,0.004214264,0.05712755,0.00033455272,0.0025632815,0.06011192],"study_design_scores_gemma":[0.5399032,0.44979554,0.003917787,0.000017176888,0.00033118745,0.0001388651,0.000023447794,0.0009776079,0.0032903992,0.00019099799,0.0013816308,0.0000321085],"about_ca_topic_score_codex":0.0008640112,"about_ca_topic_score_gemma":0.0024157555,"teacher_disagreement_score":0.0043942407,"about_ca_system_score_codex":0.0015180525,"about_ca_system_score_gemma":0.0024472917,"threshold_uncertainty_score":0.018462598},"labels":[],"label_agreement":null},{"id":"W2789468111","doi":"10.1007/s11523-018-0559-0","title":"Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ipsen; Canadian Centre for Applied Research in Cancer Control","keywords":"Cabozantinib; Medicine; Sunitinib; Internal medicine; Sorafenib; Oncology; Hazard ratio; Renal cell carcinoma; Meta-analysis; Bevacizumab; Temsirolimus; Progression-free survival; Subgroup analysis; Confidence interval; Overall survival; Hepatocellular carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors","score_opus":0.11091761757752623,"score_gpt":0.38345245457670035,"score_spread":0.27253483699917413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789468111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008838572,0.9889542,0.0005613591,0.0002177402,0.00013911245,0.00038775374,0.0005423909,0.00002560206,0.00033331712],"genre_scores_gemma":[0.35069275,0.6421093,0.0030542782,0.0010358127,0.0002504005,0.0013984665,0.0011164943,0.000033536555,0.00030902325],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99052924,0.005299923,0.0021296726,0.0008954434,0.00092710124,0.00021858838],"domain_scores_gemma":[0.98415726,0.011496508,0.0028243712,0.00037578007,0.00092039397,0.00022575281],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01326933,0.0021061962,0.015026677,0.0051707546,0.00047569943,0.0024038637,0.0017616289,0.0016988203,0.002621916],"category_scores_gemma":[0.025253056,0.0009984529,0.032493293,0.0050391727,0.00059777166,0.0014023895,0.001152392,0.0014972257,0.00020851813],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042649475,0.00004300761,0.0032210618,0.3014999,0.67791474,0.00008183015,0.00006287516,0.0007035677,0.00021946112,0.00013879334,0.00042358536,0.011426274],"study_design_scores_gemma":[0.0013207914,0.00029734403,0.0026326433,0.016218742,0.9777849,0.000058430807,0.00002778804,0.00029163988,0.00008878293,0.0001843285,0.0010774394,0.000017158929],"about_ca_topic_score_codex":0.0068922485,"about_ca_topic_score_gemma":0.015710056,"teacher_disagreement_score":0.9849733,"about_ca_system_score_codex":0.0028750326,"about_ca_system_score_gemma":0.0029361143,"threshold_uncertainty_score":0.07017577},"labels":[],"label_agreement":null},{"id":"W2900971116","doi":"10.1007/s11523-018-0603-0","title":"Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib","year":2018,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Alberta Children's Hospital Foundation","keywords":"Carfilzomib; Medicine; Cytotoxicity; Refractory (planetary science); Cancer research; Proteasome inhibitor; Leukemia; Oncology; Immunology; Multiple myeloma; In vitro; Biochemistry","score_opus":0.00839942384022,"score_gpt":0.2487751456260181,"score_spread":0.2403757217857981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900971116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959974,0.0014938185,0.0012692825,0.0000616211,0.000008351376,0.000052224634,0.00027304317,0.00003288854,0.0008113687],"genre_scores_gemma":[0.9975472,0.00072598114,0.00063040596,0.000022374634,0.000007331076,0.00003257201,0.0004146649,0.000008499333,0.00061099295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998673,0.00002302457,0.000009741336,0.000015772139,0.00004505946,0.000039082308],"domain_scores_gemma":[0.99993,0.00001593594,0.000011715,0.00001132377,0.0000134836,0.00001754211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000184906,0.00028674142,0.00044687753,0.00020976565,0.00017269814,0.00028019253,0.00017165746,0.00019736089,0.00078420027],"category_scores_gemma":[0.0001444041,0.000092533126,0.00015320977,0.00023739321,0.00016302435,0.00018318625,0.00009007367,0.00034265715,0.00021190596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000374604,0.00014851787,0.00088488706,0.00005116776,0.00001679491,0.00009956517,0.000038265873,0.00041559958,0.99249506,0.0001379931,0.000118103584,0.005219445],"study_design_scores_gemma":[0.00007391901,0.0021494483,0.009809409,0.0000046628425,0.00004138153,0.00060870755,0.000037618353,0.0017789582,0.98262733,0.000044342625,0.002819151,0.00000506307],"about_ca_topic_score_codex":0.0012075681,"about_ca_topic_score_gemma":0.0018411918,"teacher_disagreement_score":0.0012075681,"about_ca_system_score_codex":0.00037205024,"about_ca_system_score_gemma":0.00026229734,"threshold_uncertainty_score":0.0026994348},"labels":[],"label_agreement":null},{"id":"W2913025776","doi":"10.1007/s11523-018-00618-0","title":"Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Boehringer Ingelheim","keywords":"Medicine; Pharmacokinetics; Focal adhesion; Crossover; Crossover study; Pharmacology; Kinase; Pathology; Phosphorylation; Biochemistry","score_opus":0.08393497142852478,"score_gpt":0.42870015674823336,"score_spread":0.34476518531970857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913025776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917169,0.0011610105,0.001431399,0.00015715897,0.00042411656,0.0036806727,0.00064987375,0.000096633536,0.00068220595],"genre_scores_gemma":[0.9848785,0.00094179035,0.003362718,0.00047205543,0.0005332698,0.006851703,0.00080150296,0.000047106718,0.002111385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99644,0.0022638694,0.00027432074,0.00046089236,0.00027447016,0.00028643833],"domain_scores_gemma":[0.99506015,0.0015155622,0.0014138615,0.00080001884,0.00042505132,0.00078535127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053980174,0.001949314,0.0044125444,0.00049508386,0.00058027584,0.001281319,0.00088243437,0.001981713,0.0038932688],"category_scores_gemma":[0.0066198185,0.0012099151,0.0016634151,0.0007169231,0.0019067754,0.0017989778,0.00053021987,0.0037867774,0.00071898533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96651703,0.01857249,0.00062207767,0.0001472047,0.0007130557,0.000018691755,0.00006379471,0.00029130638,0.0060283663,0.000070320086,0.00028055083,0.0066751004],"study_design_scores_gemma":[0.5829831,0.40857285,0.0037623702,0.00001204887,0.00063987897,0.000029214256,0.000036118992,0.00091392035,0.0019855606,0.00017088998,0.0008625578,0.00003149919],"about_ca_topic_score_codex":0.00068391,"about_ca_topic_score_gemma":0.0011093456,"teacher_disagreement_score":0.0053980174,"about_ca_system_score_codex":0.0009588137,"about_ca_system_score_gemma":0.0013008553,"threshold_uncertainty_score":0.028547823},"labels":[],"label_agreement":null},{"id":"W2914232272","doi":"10.1007/s11523-018-00617-1","title":"Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Boehringer Ingelheim","keywords":"Medicine; Nausea; Proteinuria; Adverse effect; Peripheral edema; Internal medicine; Vomiting; Dosing; Pharmacodynamics; Pharmacokinetics; Gastroenterology; Pharmacology; Oncology; Kidney","score_opus":0.027494360188708336,"score_gpt":0.3522023992081704,"score_spread":0.3247080390194621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914232272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925195,0.002790001,0.00065626705,0.00022681626,0.000034601962,0.0016527845,0.00055264495,0.000109051005,0.0014583829],"genre_scores_gemma":[0.9931854,0.0013760012,0.0016677069,0.00044272572,0.000050989333,0.0009865991,0.0012873086,0.000016159367,0.0009869247],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999759,0.000100811616,0.000013183802,0.000038494287,0.000031507083,0.000056926143],"domain_scores_gemma":[0.999688,0.000050193208,0.000064374166,0.000022225657,0.000022199707,0.00015299533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009912362,0.0012320236,0.0013018518,0.00038089044,0.00033014707,0.0005995421,0.0006727743,0.0006147077,0.002187142],"category_scores_gemma":[0.00046237963,0.00038257483,0.00057211204,0.00040694146,0.0004505902,0.00044898683,0.0003086204,0.0016707623,0.00059331954],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2909061,0.09638848,0.036113225,0.0016841961,0.0019811853,0.0010118774,0.0010444494,0.008545019,0.22061746,0.0007280468,0.010669216,0.33031082],"study_design_scores_gemma":[0.26441717,0.6510839,0.056924637,0.000070614245,0.0007527281,0.0013098484,0.0001037217,0.0045537446,0.013639094,0.00032198726,0.006777914,0.000044686454],"about_ca_topic_score_codex":0.00084712205,"about_ca_topic_score_gemma":0.0024875728,"teacher_disagreement_score":0.002187142,"about_ca_system_score_codex":0.00062748307,"about_ca_system_score_gemma":0.0010383357,"threshold_uncertainty_score":0.0073167086},"labels":[],"label_agreement":null},{"id":"W2957412264","doi":"10.1007/s11523-019-00654-4","title":"A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton General Hospital","funders":"Meningioma Mommas","keywords":"Medicine; Integrin; Meningioma; Monoclonal antibody; Cancer research; Protein kinase B; Laminin; In vivo; In vitro; Pathology; Antibody; Cell; Phosphorylation; Immunology; Internal medicine; Biology; Receptor; Cell biology","score_opus":0.027695703254969287,"score_gpt":0.30889896636305775,"score_spread":0.28120326310808846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957412264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971289,0.0006795561,0.00062754937,0.00010156866,0.000049008057,0.00001128504,0.000081589984,0.000035934274,0.0012845373],"genre_scores_gemma":[0.99663395,0.0006966565,0.00056456955,0.000030247642,0.000012015422,0.000012847122,0.00017841882,0.000007313294,0.0018639965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999918,0.000010548388,0.0000042645847,0.000009440835,0.00001827771,0.00003948132],"domain_scores_gemma":[0.99994624,0.000010118956,0.000012790766,0.000005486057,0.000005399016,0.000020013342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010129951,0.00030456713,0.0002180769,0.00024672988,0.00017402768,0.0002480219,0.00019609195,0.00022553866,0.00094903173],"category_scores_gemma":[0.000062882245,0.00010347699,0.00020180648,0.0001664211,0.00013511717,0.00014464126,0.00007591547,0.00059078896,0.00019175027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006770536,0.00057348947,0.00023023903,0.000040971274,0.000016915035,0.00008964915,0.000024813913,0.00025477362,0.99480927,0.00014969414,0.00021295356,0.0029201945],"study_design_scores_gemma":[0.00012760922,0.0048710294,0.004975823,0.000008802358,0.000068065136,0.00038585727,0.000084817955,0.0019069267,0.98521084,0.00007397093,0.0022799887,0.0000062115564],"about_ca_topic_score_codex":0.0013417508,"about_ca_topic_score_gemma":0.0027738265,"teacher_disagreement_score":0.0013417508,"about_ca_system_score_codex":0.00025599278,"about_ca_system_score_gemma":0.00024245211,"threshold_uncertainty_score":0.0031747818},"labels":[],"label_agreement":null},{"id":"W2962334030","doi":"10.1007/s11523-019-00652-6","title":"Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Oncology; Epidermal growth factor receptor; Adenocarcinoma; Internal medicine; Resistance mutation; Cancer; Cancer research; Gefitinib; Erlotinib; Gene; Biology; Genetics; Polymerase chain reaction","score_opus":0.011041153909476078,"score_gpt":0.32929065762955295,"score_spread":0.3182495037200769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962334030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278766,0.00062412396,0.00021501446,0.0011019221,0.00003824114,0.000017325,0.00023332055,0.000015437958,0.004967049],"genre_scores_gemma":[0.99897087,0.0001380986,0.00014164424,0.00021399191,0.000041470495,0.0000021805647,0.00007795201,0.0000050869357,0.00040865346],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9998116,0.000020538571,0.00002111352,0.000044075165,0.00003475312,0.000067974746],"domain_scores_gemma":[0.9997323,0.00007825434,0.00006289059,0.000015758282,0.000026943066,0.000083800434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002116344,0.000300801,0.00039044674,0.0005693009,0.00078204914,0.00082017394,0.00037452255,0.0013345655,0.0040571326],"category_scores_gemma":[0.0007983647,0.00020370452,0.00046753432,0.00040387022,0.00043933277,0.0006014543,0.00025899694,0.0010373268,0.00048271604],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013508202,0.00035996098,0.65714014,0.000067568064,0.00009268892,0.298349,0.00045993715,0.0007012622,0.015934879,0.0016539154,0.003691678,0.020198181],"study_design_scores_gemma":[0.000119762284,0.00086640177,0.36868152,0.00008097534,0.00031176038,0.6078283,0.0013294275,0.0056853867,0.007004545,0.0021989164,0.0058358856,0.000057100064],"about_ca_topic_score_codex":0.0016664579,"about_ca_topic_score_gemma":0.002409236,"teacher_disagreement_score":0.0040571326,"about_ca_system_score_codex":0.0005985778,"about_ca_system_score_gemma":0.00046380187,"threshold_uncertainty_score":0.013572454},"labels":[],"label_agreement":null},{"id":"W2985618399","doi":"10.1007/s11523-019-00689-7","title":"High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Breast cancer; Internal medicine; Mutation; Immunology; Cancer; Genetics; Gene","score_opus":0.022687232918031704,"score_gpt":0.2912074542816495,"score_spread":0.2685202213636178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985618399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750022,0.017850874,0.0014803715,0.0025337695,0.00012159558,0.000010769006,0.00064877816,0.0000470967,0.0023044492],"genre_scores_gemma":[0.9955485,0.002465208,0.0006018638,0.00020349471,0.00027912884,0.000007182262,0.0003979746,0.000010947726,0.00048559697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995771,0.00013615965,0.000042009837,0.00009522306,0.00006714491,0.00008235675],"domain_scores_gemma":[0.9977487,0.0009389965,0.0008498026,0.0001366759,0.00013413554,0.00019168749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001257934,0.00043414708,0.00059415906,0.0008204573,0.00032305467,0.0014384552,0.00054469897,0.0006953322,0.0030984902],"category_scores_gemma":[0.0041642943,0.00026165243,0.0005043751,0.0014224733,0.00043018517,0.0010643476,0.00050431886,0.0010892157,0.00036759043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042888647,0.0000775912,0.97450835,0.00005349273,0.000259659,0.00016540747,0.00004114919,0.00033140846,0.0011543971,0.00030521923,0.0005685289,0.022105893],"study_design_scores_gemma":[0.000024725832,0.0001745845,0.9907347,0.000050343715,0.00029879643,0.00089571753,0.00026071677,0.0026550244,0.00065385766,0.001954729,0.0022771035,0.000019595163],"about_ca_topic_score_codex":0.00076647825,"about_ca_topic_score_gemma":0.001490673,"teacher_disagreement_score":0.0030984902,"about_ca_system_score_codex":0.00023154377,"about_ca_system_score_gemma":0.00038557497,"threshold_uncertainty_score":0.010365486},"labels":[],"label_agreement":null},{"id":"W2989651221","doi":"10.1007/s11523-019-00685-x","title":"Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Prostate; Cancer; Hormone","score_opus":0.06205601479162649,"score_gpt":0.388488184776486,"score_spread":0.3264321699848595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989651221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618856,0.009788268,0.020939758,0.00058456947,0.00018842664,0.0005372297,0.0038334331,0.00028370073,0.001959098],"genre_scores_gemma":[0.9892697,0.00066067226,0.005826938,0.0002615207,0.00010281891,0.00026236702,0.003034496,0.00010544798,0.00047602662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9573145,0.038154006,0.0009601153,0.0015053056,0.0017285339,0.0003375167],"domain_scores_gemma":[0.8717231,0.10153758,0.012232807,0.011447627,0.0023056236,0.00075319735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.051645413,0.0011034486,0.001548843,0.000646997,0.00023290834,0.00095502054,0.0011996381,0.00072744634,0.0018767329],"category_scores_gemma":[0.082389034,0.00038375994,0.006062255,0.00090800284,0.00046445068,0.0006916473,0.0010865823,0.0016407602,0.00023246287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19120687,0.0010535838,0.47804275,0.003194566,0.081937805,0.0002318156,0.0009755386,0.049887925,0.0023410972,0.0012897137,0.0065474487,0.18329099],"study_design_scores_gemma":[0.038373433,0.04498471,0.7236955,0.0004501979,0.07760158,0.0007716956,0.00058322644,0.09087846,0.0045724805,0.0033715356,0.0143372,0.0003799929],"about_ca_topic_score_codex":0.003329161,"about_ca_topic_score_gemma":0.0021924826,"teacher_disagreement_score":0.051645413,"about_ca_system_score_codex":0.0005831915,"about_ca_system_score_gemma":0.0007887302,"threshold_uncertainty_score":0.2731303},"labels":[],"label_agreement":null},{"id":"W3092483376","doi":"10.1007/s11523-020-00748-4","title":"Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Amgen","keywords":"Medicine; Rituximab; Internal medicine; Follicular lymphoma; Clinical endpoint; Confidence interval; CD20; Randomized controlled trial; Lymphoma; Gastroenterology; Ofatumumab; Oncology","score_opus":0.030366827538506908,"score_gpt":0.2829847304425309,"score_spread":0.252617902904024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092483376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943473,0.0042123124,0.00006729186,0.00029092285,0.0000517797,0.00011772822,0.0002564791,0.000014194851,0.00064194185],"genre_scores_gemma":[0.9963601,0.0014763401,0.00023600769,0.000389233,0.00018141246,0.00028049524,0.00058951386,0.000008980504,0.00047789418],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988887,0.0006759794,0.00009871362,0.00013878195,0.0001210801,0.00007675605],"domain_scores_gemma":[0.9985055,0.00042551584,0.0005317016,0.00012499387,0.00009806624,0.00031429806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023831122,0.00071607914,0.0017274604,0.0003292393,0.00027347333,0.0008523831,0.000632923,0.0011109393,0.0021444345],"category_scores_gemma":[0.0025323238,0.000301874,0.0012217823,0.0003962517,0.00077205425,0.00096067734,0.0003899011,0.0014952231,0.00040500643],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93649226,0.002774459,0.010075957,0.00096205855,0.0029601795,0.000117535594,0.0001326549,0.0004998736,0.006526176,0.00011623486,0.00078402326,0.038558558],"study_design_scores_gemma":[0.67154545,0.24227999,0.07190725,0.0002665473,0.0058407914,0.0005075013,0.00015843558,0.0013983512,0.0021578947,0.00048545757,0.0033739882,0.00007840565],"about_ca_topic_score_codex":0.00031793135,"about_ca_topic_score_gemma":0.00056392414,"teacher_disagreement_score":0.0023831122,"about_ca_system_score_codex":0.0007414455,"about_ca_system_score_gemma":0.0006825133,"threshold_uncertainty_score":0.012603283},"labels":[],"label_agreement":null},{"id":"W3095962378","doi":"10.1007/s11523-020-00770-6","title":"Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Everolimus; Exemestane; Oncology; Internal medicine; Hazard ratio; Breast cancer; Odds ratio; Metastatic breast cancer; Meta-analysis; Confidence interval; Cancer; Aromatase","score_opus":0.06320616612665578,"score_gpt":0.4072449643067012,"score_spread":0.34403879818004546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095962378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031771571,0.99562484,0.00032399167,0.00011034253,0.000087768596,0.00010524902,0.0003824896,0.0000175735,0.0001706084],"genre_scores_gemma":[0.10755803,0.8882884,0.0016710756,0.0009752072,0.00016420221,0.00035228115,0.00053755793,0.000029511344,0.00042380305],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99649614,0.0014473863,0.0010320827,0.00044051802,0.00040052267,0.00018337107],"domain_scores_gemma":[0.99478596,0.0034454435,0.001146332,0.00018650704,0.0003344997,0.000101197315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005441783,0.002309907,0.013625161,0.0033057109,0.0004579552,0.0023380003,0.0017937159,0.0019521744,0.0052591306],"category_scores_gemma":[0.0127605805,0.0012747432,0.02194486,0.005440428,0.0005482903,0.0018346198,0.0017372031,0.0019149182,0.00044604807],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020633054,0.000032150823,0.0031213402,0.45588294,0.52044505,0.00013495414,0.00009595462,0.00040867357,0.0003294454,0.0001508083,0.00095299876,0.016382322],"study_design_scores_gemma":[0.00079197664,0.00014108428,0.0031398383,0.020269284,0.9727936,0.000095257965,0.000052123436,0.000116365845,0.00007571637,0.00016924867,0.0023297009,0.000025974465],"about_ca_topic_score_codex":0.0056913174,"about_ca_topic_score_gemma":0.022438224,"teacher_disagreement_score":0.013625161,"about_ca_system_score_codex":0.0015562203,"about_ca_system_score_gemma":0.002432972,"threshold_uncertainty_score":0.028779268},"labels":[],"label_agreement":null},{"id":"W3111069302","doi":"10.1007/s11523-020-00778-y","title":"Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Nivolumab; Internal medicine; Population; Cohort; Retrospective cohort study; Oncology; Cancer; Immunotherapy; Environmental health","score_opus":0.03138123723126232,"score_gpt":0.29211950405521697,"score_spread":0.2607382668239546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111069302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972996,0.00027720866,0.000037116006,0.00011526565,0.0000050414624,0.000010113418,0.0020252345,0.000002204141,0.00022831676],"genre_scores_gemma":[0.99826247,0.00016773482,0.00006350965,0.00006779252,0.0000106228335,0.000016748474,0.001373991,0.0000011214016,0.000036101395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867404,0.0004435595,0.00024019623,0.00024681893,0.0002285381,0.00016682076],"domain_scores_gemma":[0.99616855,0.0004573001,0.0026510975,0.00008829756,0.00024690694,0.00038781218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087622594,0.00019440879,0.00035410756,0.0011669297,0.00029779912,0.0008164354,0.00044965392,0.00046337815,0.00081391475],"category_scores_gemma":[0.0031911526,0.0002271956,0.0006319414,0.0025854784,0.00023179424,0.0005987692,0.0006582302,0.0005963038,0.00013408743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006189173,0.000024958372,0.9990589,0.000009512754,0.00006801699,0.00003458682,0.000041874926,0.000048098245,0.000024618856,0.000013344597,0.00016438989,0.0004498342],"study_design_scores_gemma":[0.0000070904166,0.000046159897,0.9987204,0.000013433721,0.000031645854,0.00015329513,0.00032949835,0.00040421754,0.000025786432,0.000014975139,0.0002483465,0.0000051176544],"about_ca_topic_score_codex":0.025278926,"about_ca_topic_score_gemma":0.032061905,"teacher_disagreement_score":0.025278926,"about_ca_system_score_codex":0.0011676536,"about_ca_system_score_gemma":0.00072845013,"threshold_uncertainty_score":0.050263584},"labels":[],"label_agreement":null},{"id":"W3157804315","doi":"10.1007/s11523-021-00813-6","title":"Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies","year":2021,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sumitomo Dainippon Pharma Oncology","keywords":"Medicine; Tolerability; Adverse effect; Discontinuation; Internal medicine; Phases of clinical research; Cancer; Dosing; Oncology; Clinical trial","score_opus":0.012801173832122325,"score_gpt":0.31028738123255467,"score_spread":0.29748620740043236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157804315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509144,0.00081358844,0.0006073101,0.0001776456,0.000058039393,0.0017016644,0.0005164462,0.00008205843,0.0009518324],"genre_scores_gemma":[0.9937412,0.0006358914,0.0015697625,0.0003658718,0.00014172209,0.0015025461,0.0009524024,0.000024050436,0.0010665292],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995546,0.00019314009,0.000026289268,0.0000969208,0.000054602082,0.00007445959],"domain_scores_gemma":[0.9992893,0.00011199492,0.0001619981,0.000069298054,0.00005272878,0.0003145967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001674625,0.0013718964,0.0018035879,0.0003514761,0.00041945552,0.00080434146,0.0007682343,0.00085971324,0.0027992388],"category_scores_gemma":[0.0009974807,0.0005036703,0.00078575657,0.00043429068,0.0008225353,0.000887725,0.00035360406,0.0030698571,0.0008807833],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6180591,0.1379851,0.015826924,0.0007516209,0.0010358386,0.00041509184,0.00061119604,0.0038775771,0.10283147,0.0002888168,0.004252036,0.114065185],"study_design_scores_gemma":[0.3465169,0.6325609,0.0121156825,0.000019114483,0.00027084185,0.0002943759,0.00006289342,0.0013371647,0.0044466117,0.00010796012,0.0022452162,0.000022213018],"about_ca_topic_score_codex":0.00047343827,"about_ca_topic_score_gemma":0.00079078623,"teacher_disagreement_score":0.0027992388,"about_ca_system_score_codex":0.0006739605,"about_ca_system_score_gemma":0.0014851162,"threshold_uncertainty_score":0.009364426},"labels":[],"label_agreement":null},{"id":"W3172387625","doi":"10.1007/s11523-021-00822-5","title":"Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Narodowe Centrum Nauki","keywords":"Medicine; Meta-analysis; Oncology; Targeted therapy; Clinical trial; Internal medicine; Pediatric oncology; Intensive care medicine; Cancer","score_opus":0.7192358579784843,"score_gpt":0.652057374042999,"score_spread":0.06717848393548531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172387625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054875584,0.9906238,0.001728114,0.00029544844,0.0001736504,0.000664566,0.00066848187,0.000042877004,0.00031552676],"genre_scores_gemma":[0.32106552,0.661735,0.008035656,0.0016961453,0.0005416544,0.004948238,0.001396307,0.00008329005,0.0004982355],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9658879,0.01935524,0.008714155,0.002648368,0.0028364542,0.000557907],"domain_scores_gemma":[0.922038,0.06309611,0.009804789,0.0018695018,0.0026908352,0.0005007108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03423872,0.0033053933,0.022515932,0.008481128,0.00068367075,0.004010059,0.0024328236,0.0025313522,0.0036943816],"category_scores_gemma":[0.079865865,0.0018960139,0.05429957,0.009739842,0.0010670124,0.003134055,0.0019901688,0.0024469667,0.00034018586],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001774983,0.000016275224,0.00415546,0.24212164,0.74399424,0.000103215156,0.00006169975,0.0006127778,0.00010980429,0.00015157762,0.00047462972,0.0064237365],"study_design_scores_gemma":[0.000690057,0.00014086872,0.0023466807,0.017494095,0.9777115,0.00006874009,0.00003163472,0.00027684958,0.000061744155,0.00028579112,0.0008718589,0.000020239153],"about_ca_topic_score_codex":0.004288611,"about_ca_topic_score_gemma":0.0088713765,"teacher_disagreement_score":0.03423872,"about_ca_system_score_codex":0.0031492212,"about_ca_system_score_gemma":0.0035227106,"threshold_uncertainty_score":0.18107378},"labels":[],"label_agreement":null},{"id":"W4238104384","doi":"10.1007/s11523-020-00772-4","title":"Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Paragraph; Rituximab; Follicular lymphoma; Lymphoma; Internal medicine; Medical physics; Oncology; World Wide Web","score_opus":0.022459294506606785,"score_gpt":0.2756866625027647,"score_spread":0.2532273679961579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238104384","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001310794,0.0013443809,0.00031118907,0.08255854,0.9122275,0.00004102745,0.0014769813,0.00027840165,0.0016308096],"genre_scores_gemma":[0.0099301,0.0067929425,0.003043107,0.27239767,0.59893,0.0004423868,0.0029415546,0.001296739,0.10422548],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99208164,0.0015414995,0.0017420466,0.00089217915,0.0029971253,0.00074548303],"domain_scores_gemma":[0.9447288,0.021369303,0.0031559397,0.0024388735,0.026082171,0.002224805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068957354,0.0024467213,0.0030037616,0.0030523995,0.002152738,0.0048344545,0.0042300127,0.011761221,0.04952354],"category_scores_gemma":[0.105650954,0.0016928995,0.00330531,0.0024198615,0.002286391,0.0017647655,0.0013401603,0.01886864,0.02795099],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008222894,0.000005594079,0.00003638386,0.00016603194,0.000019743244,0.000074709744,0.0000108051145,0.000021785776,0.000028563192,0.00014596703,0.9974795,0.0019286777],"study_design_scores_gemma":[0.0006536356,0.00010136173,0.0019291018,0.0012526076,0.00022562861,0.0005542048,0.0000714983,0.0004220189,0.00050922116,0.0016312358,0.99257445,0.00007490629],"about_ca_topic_score_codex":0.017814733,"about_ca_topic_score_gemma":0.016711606,"teacher_disagreement_score":0.04952354,"about_ca_system_score_codex":0.0051782876,"about_ca_system_score_gemma":0.0064805313,"threshold_uncertainty_score":0.16567272},"labels":[],"label_agreement":null},{"id":"W4281722441","doi":"10.1007/s11523-022-00884-z","title":"A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Neratinib; Cancer; Epidermal growth factor receptor; Breast cancer; Clinical trial; Erlotinib; Phases of clinical research; Trastuzumab","score_opus":0.06037269198487216,"score_gpt":0.3976504848924063,"score_spread":0.3372777929075341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281722441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98597217,0.0030882051,0.0007900615,0.002469093,0.00035089476,0.0010157006,0.0027660364,0.00016217482,0.0033856463],"genre_scores_gemma":[0.98523986,0.00261724,0.0015126528,0.0020542943,0.00017159533,0.001187861,0.003737564,0.000076326796,0.0034026057],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964106,0.0001265681,0.00001679827,0.00007114495,0.000030297013,0.00011408856],"domain_scores_gemma":[0.9994307,0.00009215496,0.0000985929,0.00004626071,0.000037064547,0.00029518257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012647845,0.0019988234,0.0025688868,0.0003875295,0.00045412043,0.0013693712,0.00077179243,0.0016952334,0.0049867798],"category_scores_gemma":[0.0011600124,0.00049130537,0.0020624353,0.00051772554,0.0008146584,0.0015303188,0.00055183686,0.0035595787,0.0011255875],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8093213,0.011441811,0.00713887,0.0010612359,0.0043111467,0.00065211905,0.00032972672,0.00516824,0.028857647,0.0015599709,0.016345073,0.11381294],"study_design_scores_gemma":[0.88449013,0.09604952,0.00793211,0.000049121696,0.00089857244,0.00065807963,0.000119220844,0.0014982321,0.0017496241,0.0013893266,0.0050863433,0.00007971885],"about_ca_topic_score_codex":0.0011625837,"about_ca_topic_score_gemma":0.0037641241,"teacher_disagreement_score":0.0049867798,"about_ca_system_score_codex":0.0010632601,"about_ca_system_score_gemma":0.0013020724,"threshold_uncertainty_score":0.016682506},"labels":[],"label_agreement":null},{"id":"W4283026383","doi":"10.1007/s11523-022-00888-9","title":"Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Refractory (planetary science); Multicenter study; Phases of clinical research; Internal medicine; Oncology; Clinical trial; Randomized controlled trial","score_opus":0.008484783094617332,"score_gpt":0.27110953133376103,"score_spread":0.2626247482391437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283026383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960134,0.0021687646,0.00017343035,0.00018835528,0.000024224597,0.0005120433,0.00036258975,0.000032523385,0.00052469166],"genre_scores_gemma":[0.9916163,0.0034371554,0.0012935875,0.00049764465,0.00009179586,0.000903154,0.0015037624,0.00001576157,0.0006408363],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99977404,0.00009623088,0.000018934152,0.00003268204,0.000030927542,0.000047183385],"domain_scores_gemma":[0.9995516,0.000038288574,0.00012502224,0.000025739291,0.00003396715,0.00022536583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012303859,0.00088257267,0.0013484758,0.00023481165,0.0002500215,0.0005309952,0.00040752298,0.0004591137,0.00089665304],"category_scores_gemma":[0.0005034858,0.00030906973,0.000696842,0.0003409209,0.0003341776,0.0004271804,0.00022021338,0.0016091741,0.0003535744],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3652004,0.07223995,0.07875925,0.0016322805,0.0028259885,0.0017085739,0.001051242,0.005158389,0.1396117,0.0005275343,0.0102602905,0.3210243],"study_design_scores_gemma":[0.2631934,0.569565,0.13292606,0.00012204976,0.0014261316,0.0028452987,0.00024019401,0.004021308,0.014295671,0.00019404758,0.011113216,0.000057593646],"about_ca_topic_score_codex":0.0009891071,"about_ca_topic_score_gemma":0.0028097858,"teacher_disagreement_score":0.0013484758,"about_ca_system_score_codex":0.0007170174,"about_ca_system_score_gemma":0.0014077894,"threshold_uncertainty_score":0.0065069795},"labels":[],"label_agreement":null},{"id":"W4301600257","doi":"10.1007/s11523-022-00920-y","title":"Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Hospital","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical endpoint; Clinical trial; Internal medicine; Confidence interval; Biomarker; Surrogate endpoint; Phases of clinical research; Oncology","score_opus":0.7138172971596959,"score_gpt":0.6583019463492661,"score_spread":0.0555153508104298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301600257","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32007778,0.049264677,0.5463263,0.06153005,0.0031716952,0.0016767565,0.004759487,0.0012851927,0.011908149],"genre_scores_gemma":[0.94054997,0.002997075,0.041723836,0.008633679,0.0016290152,0.0009219634,0.0015765424,0.00028915933,0.0016786528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8344014,0.14390567,0.0064431126,0.007815276,0.0049636946,0.002470899],"domain_scores_gemma":[0.25820518,0.66794664,0.03762921,0.02807684,0.005349829,0.0027923733],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.23241833,0.00216739,0.0063484833,0.0017030298,0.00080974126,0.0064221793,0.003191791,0.003902836,0.006368218],"category_scores_gemma":[0.5461636,0.0014273096,0.0051902793,0.0027586415,0.0054267403,0.013314194,0.0026959314,0.0077027436,0.001954154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029235767,0.0013700024,0.44362697,0.005226948,0.019165209,0.00042929553,0.0011003971,0.048636258,0.0017119121,0.07432253,0.026825069,0.3483496],"study_design_scores_gemma":[0.007766121,0.009051729,0.15267445,0.0020702516,0.0134281,0.0015834857,0.0007833307,0.21586408,0.0043751555,0.5606273,0.031416006,0.00036007154],"about_ca_topic_score_codex":0.0008603447,"about_ca_topic_score_gemma":0.0011941832,"teacher_disagreement_score":0.7675817,"about_ca_system_score_codex":0.0012725216,"about_ca_system_score_gemma":0.004589527,"threshold_uncertainty_score":0.94656485},"labels":[],"label_agreement":null},{"id":"W4310595717","doi":"10.1007/s11523-022-00931-9","title":"Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Mirati Therapeutics","keywords":"Medicine; Nausea; Pharmacokinetics; Vomiting; Adverse effect; Internal medicine; Gastroenterology; Cancer; Response Evaluation Criteria in Solid Tumors; Capsule; Pharmacology; Chemotherapy; Progressive disease","score_opus":0.017397823526277143,"score_gpt":0.3924252135381065,"score_spread":0.37502739001182933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310595717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887862,0.0028548744,0.00057486776,0.0009224809,0.00021279117,0.0017634709,0.001997317,0.00011661618,0.0027713939],"genre_scores_gemma":[0.98453414,0.003081286,0.0014987824,0.0013304321,0.00017453685,0.0013904952,0.004373681,0.000042461586,0.003574138],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997564,0.00009235429,0.000009250109,0.00004812122,0.000020164096,0.00007370201],"domain_scores_gemma":[0.9995314,0.000060659444,0.00006512235,0.000024713154,0.000025964453,0.0002920834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010282476,0.0014956596,0.0019218946,0.00038075072,0.0003978983,0.001127387,0.00075964665,0.0010687674,0.0032166082],"category_scores_gemma":[0.00057844527,0.00058763847,0.0017147315,0.00044284068,0.00078398176,0.0007262463,0.00033780996,0.0035193376,0.0007485802],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7593347,0.064107485,0.008784422,0.0010918323,0.0028543915,0.0004317677,0.00031593983,0.00702561,0.048991997,0.0007069671,0.010796953,0.09555792],"study_design_scores_gemma":[0.64713913,0.32881063,0.013869073,0.000045303954,0.00083501334,0.0003460529,0.000104430634,0.0019906063,0.00280202,0.00031217872,0.0037071097,0.00003851135],"about_ca_topic_score_codex":0.002689654,"about_ca_topic_score_gemma":0.0085053295,"teacher_disagreement_score":0.0032166082,"about_ca_system_score_codex":0.0011338859,"about_ca_system_score_gemma":0.001904595,"threshold_uncertainty_score":0.010760605},"labels":[],"label_agreement":null},{"id":"W4317209129","doi":"10.1007/s11523-022-00941-7","title":"Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Lung cancer; Central nervous system; Lung; Oncology; Pathology; Cancer; Cancer research; Internal medicine; Adenocarcinoma","score_opus":0.0675653515167773,"score_gpt":0.43998593053210705,"score_spread":0.37242057901532977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317209129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018448399,0.99882036,0.000060910555,0.00016924668,0.00009943598,0.000004893038,0.000033719134,0.000004595339,0.000622294],"genre_scores_gemma":[0.000969062,0.99811053,0.0001229399,0.00022721099,0.000072332776,0.000006095106,0.000047609436,0.0000010986084,0.00044312148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990284,0.000016396321,0.000016380833,0.000018040615,0.00003067931,0.000015787826],"domain_scores_gemma":[0.99983454,0.00008251108,0.000034518933,0.0000032801975,0.000031768956,0.000013296296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044975334,0.0005935664,0.0013880995,0.00094181293,0.00012355494,0.0008691061,0.0005768921,0.0005884882,0.0042123743],"category_scores_gemma":[0.0005344896,0.00015425832,0.00066413044,0.0011449946,0.00019369791,0.0006773317,0.00039331865,0.0012894819,0.0010297201],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002209716,0.000055079876,0.00013062502,0.01740801,0.00023349094,0.00008406291,0.000023856743,0.00038464222,0.0011646386,0.0014624991,0.020069728,0.95876247],"study_design_scores_gemma":[0.00027398497,0.0003928934,0.0015580407,0.008861538,0.0011332182,0.0008960186,0.00006158295,0.00028618137,0.0006347464,0.0019291274,0.98394287,0.000029740744],"about_ca_topic_score_codex":0.0010495746,"about_ca_topic_score_gemma":0.0038526778,"teacher_disagreement_score":0.0042123743,"about_ca_system_score_codex":0.0004335073,"about_ca_system_score_gemma":0.00079565035,"threshold_uncertainty_score":0.01409179},"labels":[],"label_agreement":null},{"id":"W4319460408","doi":"10.1007/s11523-023-00947-9","title":"Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies","year":2023,"lang":"en","type":"erratum","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Lung cancer; Central nervous system; Lung; Oncology; Mutant; Cancer; Cancer research; Neuroscience; Internal medicine; Epidermal growth factor receptor; Erlotinib; Biology; Gene","score_opus":0.026562778920250763,"score_gpt":0.37817529279251416,"score_spread":0.3516125138722634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319460408","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007187173,0.0014068421,0.00032009912,0.0440828,0.9518409,0.000016555976,0.00042719446,0.00010490127,0.0017288148],"genre_scores_gemma":[0.007045124,0.011773802,0.0032993767,0.12422624,0.67582583,0.00015014682,0.0011236693,0.00081157766,0.17574418],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976203,0.0003922867,0.00041546024,0.00032035098,0.0009903985,0.00026127987],"domain_scores_gemma":[0.9867697,0.0039539873,0.0008126127,0.00053698965,0.0069275293,0.0009992705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003035175,0.0016918845,0.0017300163,0.0024401625,0.0019018956,0.0030325297,0.0022841978,0.0067859814,0.035665095],"category_scores_gemma":[0.031837523,0.00078395446,0.0016890102,0.0012213239,0.001746032,0.0013723752,0.0011966435,0.01048221,0.01782301],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027337052,0.0000034333286,0.000036528098,0.000100257945,0.000009593004,0.0003014646,0.000008786336,0.0000335231,0.000027937358,0.000309079,0.9949274,0.0042146356],"study_design_scores_gemma":[0.00006673236,0.000018212566,0.00036626175,0.00031918526,0.00004842449,0.0011161881,0.00003203552,0.00020620417,0.00021330868,0.0008527751,0.9967353,0.000025379162],"about_ca_topic_score_codex":0.014948138,"about_ca_topic_score_gemma":0.022230785,"teacher_disagreement_score":0.035665095,"about_ca_system_score_codex":0.003616522,"about_ca_system_score_gemma":0.0052072187,"threshold_uncertainty_score":0.11931163},"labels":[],"label_agreement":null},{"id":"W4366351020","doi":"10.1007/s11523-023-00957-7","title":"Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Palbociclib; Targeted therapy; Chemotherapy; Cyclin-dependent kinase 4; Cancer; Clinical trial; Cell cycle; Cyclin-dependent kinase 2","score_opus":0.03738858245496208,"score_gpt":0.39182272420085024,"score_spread":0.35443414174588816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366351020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017952372,0.998922,0.000053360996,0.00032136944,0.0001519425,0.00002575165,0.000056747147,0.0000030246345,0.0002863929],"genre_scores_gemma":[0.0013114772,0.9978169,0.00016246222,0.0004254459,0.00011008019,0.000036307243,0.00005285525,0.0000015676093,0.00008285455],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977717,0.0005762371,0.0009143932,0.00019049676,0.00044354217,0.00010358631],"domain_scores_gemma":[0.99068683,0.0061844354,0.0015480771,0.00011598061,0.0013176242,0.00014708577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003084362,0.0010472938,0.0035526918,0.010428008,0.00048474927,0.002056062,0.0013962422,0.0018066156,0.0042313063],"category_scores_gemma":[0.0101450775,0.0006262527,0.002901756,0.012213545,0.0005386778,0.0024347536,0.0010654437,0.0011591022,0.00064516574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020107652,0.000053518095,0.0005355667,0.7125571,0.0012711366,0.00032313517,0.0003574182,0.00023807392,0.00057080714,0.0013179821,0.013121367,0.26945284],"study_design_scores_gemma":[0.00009078503,0.00021781045,0.0027743843,0.79554725,0.011339465,0.0013083766,0.00043530588,0.00011474531,0.00028692582,0.0009587787,0.18689072,0.0000354242],"about_ca_topic_score_codex":0.0046398416,"about_ca_topic_score_gemma":0.009005884,"teacher_disagreement_score":0.010428008,"about_ca_system_score_codex":0.0023935542,"about_ca_system_score_gemma":0.0072705555,"threshold_uncertainty_score":0.017366588},"labels":[],"label_agreement":null},{"id":"W4379509021","doi":"10.1007/s11523-023-00965-7","title":"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Insect Resistance and Genetics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"AstraZeneca","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Pharmacology; Adverse effect","score_opus":0.007141951924465786,"score_gpt":0.3043287191005847,"score_spread":0.2971867671761189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379509021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99381095,0.0013058364,0.00041071864,0.00016907482,0.0000692341,0.0021823507,0.000718371,0.00004349329,0.0012900274],"genre_scores_gemma":[0.9917167,0.0011641023,0.0011723601,0.000439547,0.00010894887,0.002014798,0.0020157418,0.00001915327,0.0013486604],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996588,0.00013734182,0.000021943508,0.00006199325,0.000037658476,0.00008224638],"domain_scores_gemma":[0.9992756,0.00009354044,0.00013021927,0.000059799117,0.000049692077,0.0003911508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013018945,0.0010630843,0.0017059564,0.0003320964,0.0004312155,0.00081011746,0.0005652854,0.00075989176,0.003422021],"category_scores_gemma":[0.0006636727,0.00041778645,0.0009374303,0.00039736537,0.0006928348,0.0006523038,0.0002748957,0.0023195953,0.00089234265],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6225053,0.12196401,0.014273303,0.0014255748,0.0014363776,0.00051865366,0.00041607284,0.0030054252,0.108476155,0.0003070601,0.0037291588,0.12194287],"study_design_scores_gemma":[0.29383186,0.68437976,0.012280225,0.000033054566,0.00035382464,0.0003875467,0.00006997832,0.00089851196,0.004950139,0.00013925094,0.0026567427,0.00001922036],"about_ca_topic_score_codex":0.0006661885,"about_ca_topic_score_gemma":0.0013670335,"teacher_disagreement_score":0.003422021,"about_ca_system_score_codex":0.0008054909,"about_ca_system_score_gemma":0.0018339673,"threshold_uncertainty_score":0.011447787},"labels":[],"label_agreement":null},{"id":"W4386346584","doi":"10.1007/s11523-023-00995-1","title":"Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba; University of Calgary","funders":"Jazz Pharmaceuticals Canada","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Population; Internal medicine; Oncology; Chemotherapy; Surgery; Environmental health","score_opus":0.027790270941448557,"score_gpt":0.3760701408180536,"score_spread":0.3482798698766051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386346584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563554,0.029535554,0.00056313764,0.0010414207,0.0002969749,0.0011049077,0.0037067544,0.000055505105,0.0073403963],"genre_scores_gemma":[0.99211204,0.0041189264,0.00055886764,0.0003299142,0.00010700476,0.00015432922,0.0013123138,0.0000149837915,0.0012916565],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957777,0.002541528,0.00017368938,0.0004087004,0.00063680846,0.0004614944],"domain_scores_gemma":[0.9962005,0.0011888503,0.0009844032,0.00032130547,0.0004893264,0.00081563444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049249376,0.0012236189,0.0026127768,0.0008893671,0.0006272535,0.0016176592,0.0016170301,0.0014158391,0.0030204253],"category_scores_gemma":[0.0064087682,0.00049084006,0.0032934616,0.001658081,0.001642048,0.00081323175,0.0005258993,0.0024638225,0.00024173612],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9424806,0.0026548565,0.004203841,0.0012106391,0.0057186005,0.00006273012,0.00012854788,0.0025486888,0.0016280161,0.0007071877,0.0016312113,0.037025087],"study_design_scores_gemma":[0.59396666,0.23421179,0.122226134,0.0006222131,0.028496146,0.00023344845,0.00041690195,0.0048221173,0.0021013117,0.00064226805,0.011989527,0.00027147194],"about_ca_topic_score_codex":0.34747925,"about_ca_topic_score_gemma":0.48180413,"teacher_disagreement_score":0.6525208,"about_ca_system_score_codex":0.017499782,"about_ca_system_score_gemma":0.010863451,"threshold_uncertainty_score":0.69091344},"labels":[],"label_agreement":null},{"id":"W4386387581","doi":"10.1007/s11523-023-00987-1","title":"Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Placebo; Nephrectomy; Internal medicine; Adjuvant; Oncology; Adjuvant therapy; Kidney cancer; Clinical trial; Cancer; Surgery; Immunotherapy; Kidney; Pathology; Alternative medicine","score_opus":0.12948190054941494,"score_gpt":0.4061370170159111,"score_spread":0.27665511646649615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386387581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4446293,0.38565534,0.0063569746,0.02325095,0.014443812,0.05520126,0.029482996,0.0011760959,0.039803322],"genre_scores_gemma":[0.79665935,0.10742691,0.0076018553,0.020344833,0.008347743,0.025517333,0.010702079,0.00016613734,0.023233775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988682,0.00063511386,0.00013745784,0.00014949379,0.00012097939,0.00008879966],"domain_scores_gemma":[0.9980983,0.0008070579,0.00047945365,0.000091610724,0.00021259015,0.0003108552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035168768,0.001500574,0.0027320997,0.00049662025,0.00045443894,0.0018260344,0.00097199605,0.0028226518,0.019142417],"category_scores_gemma":[0.0042703343,0.00067958084,0.0037293578,0.00048439822,0.0005838756,0.0008638684,0.00029161794,0.0026826449,0.0029683388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8709019,0.0043842006,0.00069387245,0.022689098,0.010911472,0.00009937903,0.000080862796,0.0005180157,0.0043456103,0.00059406535,0.014959364,0.0698223],"study_design_scores_gemma":[0.9611006,0.026379371,0.0012854366,0.0009804603,0.0043950253,0.00004209,0.000021156311,0.0001926937,0.00041838177,0.00031995063,0.004840447,0.000024387018],"about_ca_topic_score_codex":0.00076330244,"about_ca_topic_score_gemma":0.00180104,"teacher_disagreement_score":0.019142417,"about_ca_system_score_codex":0.0006777559,"about_ca_system_score_gemma":0.0014896472,"threshold_uncertainty_score":0.0640378},"labels":[],"label_agreement":null},{"id":"W4387032788","doi":"10.1007/s11523-023-01000-5","title":"A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Observational study; Gemcitabine; Cochrane Library; Internal medicine; MEDLINE; Chemotherapy; Cancer; Biliary tract cancer; Oncology; Intensive care medicine; Meta-analysis","score_opus":0.08894734557234671,"score_gpt":0.4349304150010871,"score_spread":0.34598306942874035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387032788","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040357234,0.9865876,0.0004887846,0.0016176406,0.00035074964,0.0012231589,0.004693605,0.00002769095,0.00097497535],"genre_scores_gemma":[0.029143011,0.9570967,0.0046475367,0.0020518575,0.00022717527,0.0029704885,0.003497056,0.000020103467,0.0003461427],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.96647435,0.008105199,0.02027774,0.001502253,0.0031297612,0.000510643],"domain_scores_gemma":[0.87387514,0.087143496,0.023944363,0.0025683597,0.011715992,0.000752578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020706996,0.0013378431,0.0063424935,0.050345577,0.0010443596,0.0041937325,0.0019808288,0.0020799746,0.0049948306],"category_scores_gemma":[0.10461428,0.001188866,0.004867364,0.04831528,0.0012899775,0.0050396654,0.0026649828,0.0011358638,0.000651892],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012112256,0.000015264211,0.001995736,0.94800586,0.0026075316,0.00021486374,0.00062772306,0.00011559171,0.00028532115,0.00052130315,0.0036277734,0.041861866],"study_design_scores_gemma":[0.000086565786,0.00011738865,0.006317731,0.9473237,0.013323155,0.0004326589,0.00070161803,0.00007273869,0.0001628057,0.00032902072,0.031099776,0.0000328158],"about_ca_topic_score_codex":0.0072729825,"about_ca_topic_score_gemma":0.02207477,"teacher_disagreement_score":0.050345577,"about_ca_system_score_codex":0.0066286107,"about_ca_system_score_gemma":0.02383468,"threshold_uncertainty_score":0.10951036},"labels":[],"label_agreement":null},{"id":"W4387930721","doi":"10.1007/s11523-023-00997-z","title":"A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Cetuximab; Medicine; Internal medicine; Head and neck squamous-cell carcinoma; Oncology; Head and neck cancer; Phases of clinical research; Cancer; Clinical trial; Colorectal cancer","score_opus":0.03311622994514312,"score_gpt":0.33711391180749295,"score_spread":0.3039976818623498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387930721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871802,0.004829042,0.00059714087,0.0006666494,0.0001816696,0.0043157083,0.00090949616,0.000104637045,0.0012153859],"genre_scores_gemma":[0.9837646,0.0038923726,0.0020472023,0.0010252801,0.0002606797,0.0042189616,0.0018897925,0.000046556415,0.002854514],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989287,0.00059696805,0.000049215872,0.00018900067,0.00010378796,0.00013232187],"domain_scores_gemma":[0.9990446,0.00016143506,0.00021940873,0.00009131926,0.00009895771,0.00038433576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029925643,0.0019599025,0.0034631353,0.00066042325,0.0004589886,0.0011132722,0.00092489214,0.0017189385,0.005276326],"category_scores_gemma":[0.0015791436,0.00104718,0.0028996638,0.00056875695,0.00086712174,0.0010082647,0.00045936153,0.0030659488,0.0012155488],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8434001,0.05909966,0.0049204677,0.0016984122,0.0026359733,0.0002672973,0.0002711865,0.0016601797,0.02537897,0.00013286828,0.002324727,0.05821006],"study_design_scores_gemma":[0.6600773,0.32638055,0.008956816,0.00003772228,0.0007471063,0.00018263626,0.00003589311,0.00073700474,0.0012995212,0.000074732576,0.001438554,0.00003213773],"about_ca_topic_score_codex":0.0013232178,"about_ca_topic_score_gemma":0.00296011,"teacher_disagreement_score":0.005276326,"about_ca_system_score_codex":0.0012194668,"about_ca_system_score_gemma":0.0019300735,"threshold_uncertainty_score":0.017651081},"labels":[],"label_agreement":null},{"id":"W4392654691","doi":"10.1007/s11523-024-01034-3","title":"Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","year":2024,"lang":"en","type":"letter","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Lung cancer; Oncology; Internal medicine; Placebo; Epidermal growth factor receptor; Stage (stratigraphy); Cancer; Pathology; Erlotinib; Biology","score_opus":0.05860293502871478,"score_gpt":0.41327494089060063,"score_spread":0.35467200586188585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392654691","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004573244,0.029964581,0.0004497937,0.8789054,0.06005795,0.0001444956,0.0010548804,0.00014314338,0.024706557],"genre_scores_gemma":[0.025344927,0.026101189,0.0008187925,0.6349901,0.28297684,0.0001932799,0.0010348542,0.000081354745,0.028458664],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845815,0.00041143503,0.00033283676,0.00020508705,0.00038564496,0.00020690759],"domain_scores_gemma":[0.9954673,0.0018614125,0.00038882674,0.0001244633,0.0015335119,0.0006243695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002686217,0.00067906454,0.0010813547,0.0006873924,0.0011424386,0.00218113,0.0010701922,0.009439343,0.005339583],"category_scores_gemma":[0.006675435,0.00026422399,0.0010509554,0.0007455698,0.00069102005,0.0013704866,0.0003161372,0.005726732,0.006628429],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070574123,0.00020389726,0.0021272828,0.0004568787,0.00005810185,0.0015539685,0.00005668171,0.00016966826,0.0008658839,0.0015130807,0.8987345,0.093554266],"study_design_scores_gemma":[0.0009409843,0.0016153301,0.008770278,0.0012668942,0.0002846323,0.004552567,0.00019287693,0.0008850071,0.0015917282,0.004088539,0.97573924,0.00007197297],"about_ca_topic_score_codex":0.002067549,"about_ca_topic_score_gemma":0.003564487,"teacher_disagreement_score":0.009439343,"about_ca_system_score_codex":0.0041434844,"about_ca_system_score_gemma":0.002082372,"threshold_uncertainty_score":0.030063272},"labels":[],"label_agreement":null},{"id":"W4393260725","doi":"10.1007/s11523-024-01046-z","title":"Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Breast cancer; Randomized controlled trial; Population; Metastatic breast cancer; Clinical trial; Oncology; Internal medicine; Cochrane Library; Cancer","score_opus":0.01904652755948039,"score_gpt":0.3726052928173543,"score_spread":0.35355876525787394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393260725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011115223,0.99779725,0.000069142014,0.0001952223,0.000055681925,0.00026692223,0.00027095503,0.000005191935,0.00022817029],"genre_scores_gemma":[0.018624589,0.97942597,0.0003918828,0.0005912774,0.0000805182,0.0005652096,0.00020960176,0.0000035882458,0.00010735233],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9958895,0.0013274421,0.0015825749,0.00031685294,0.00073563727,0.00014818598],"domain_scores_gemma":[0.9836187,0.010651291,0.0038646308,0.00017177842,0.0014496547,0.00024391596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005906344,0.0012231003,0.0076950607,0.008554496,0.00052807503,0.0019061292,0.0014598338,0.0016301358,0.003914963],"category_scores_gemma":[0.021366106,0.0008122652,0.006108284,0.008924639,0.00067753706,0.0019283566,0.0010986881,0.0009024505,0.00027354166],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023569555,0.00001575922,0.00081473053,0.9684466,0.0082646,0.000085006395,0.00009645475,0.000060455535,0.00010591704,0.000094024515,0.0011355515,0.020645237],"study_design_scores_gemma":[0.0005981581,0.00032057546,0.006032343,0.8699155,0.106123276,0.00052879774,0.00025285734,0.00012225645,0.00016148243,0.00023673465,0.015671398,0.000036668927],"about_ca_topic_score_codex":0.0077465153,"about_ca_topic_score_gemma":0.02345481,"teacher_disagreement_score":0.008554496,"about_ca_system_score_codex":0.0031148766,"about_ca_system_score_gemma":0.008915592,"threshold_uncertainty_score":0.031236112},"labels":[],"label_agreement":null},{"id":"W4399799341","doi":"10.1007/s11523-024-01076-7","title":"Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Karyopharm Therapeutics","keywords":"Medicine; Tolerability; Nausea; Adverse effect; Internal medicine; Clinical endpoint; Phases of clinical research; Vomiting; Clinical trial; Toxicity; Anorexia; Oncology; Surgery","score_opus":0.06135130984307056,"score_gpt":0.42116634898864436,"score_spread":0.3598150391455738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399799341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946727,0.0013147984,0.00042484087,0.00044986306,0.000065647226,0.00034787078,0.0008262234,0.00009322356,0.0018048462],"genre_scores_gemma":[0.99319977,0.001039073,0.00063624117,0.0005193646,0.000066574976,0.00039760995,0.0017095138,0.000040173232,0.0023917898],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995161,0.00025346605,0.000023013936,0.00006764753,0.000054053184,0.00008564181],"domain_scores_gemma":[0.99920684,0.00023506687,0.00015048339,0.000100520316,0.000043079403,0.0002640298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002092725,0.0010634252,0.00151952,0.00033748665,0.00028194077,0.00096951355,0.0004984983,0.00082136906,0.0034417033],"category_scores_gemma":[0.0011759979,0.0002722068,0.0012790839,0.00023434956,0.0009562502,0.0012335336,0.00031711583,0.0026259804,0.0009634037],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6599231,0.04303497,0.0085909,0.00091717613,0.0019770735,0.0002840063,0.00032141976,0.006588457,0.0538671,0.0006933106,0.0062239184,0.21757863],"study_design_scores_gemma":[0.33507538,0.6124582,0.032420047,0.00007263977,0.00081846875,0.00053905795,0.00020492809,0.0036460143,0.009865596,0.0009699768,0.003861248,0.00006841318],"about_ca_topic_score_codex":0.00034103452,"about_ca_topic_score_gemma":0.0009007427,"teacher_disagreement_score":0.0034417033,"about_ca_system_score_codex":0.0004897549,"about_ca_system_score_gemma":0.00063602295,"threshold_uncertainty_score":0.011513591},"labels":[],"label_agreement":null},{"id":"W4400327380","doi":"10.1007/s11523-024-01074-9","title":"A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Carboplatin; Metastatic Urothelial Carcinoma; Pembrolizumab; Oncology; Internal medicine; Cisplatin; Chemotherapy; Nivolumab; Avelumab; Atezolizumab; Urothelial carcinoma; Immunotherapy; Cancer; Bladder cancer","score_opus":0.029661348170795524,"score_gpt":0.32597582500551686,"score_spread":0.29631447683472134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400327380","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026470963,0.18485811,0.0032109416,0.47449577,0.31246778,0.0003146307,0.0033988366,0.00060535484,0.01800146],"genre_scores_gemma":[0.025330674,0.280477,0.00807283,0.2374319,0.39780885,0.0006328165,0.0053896667,0.0005966998,0.04425963],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974131,0.00083872647,0.00045303325,0.0004675224,0.00051792763,0.00030969878],"domain_scores_gemma":[0.9784167,0.009433243,0.0020295642,0.00072001107,0.0048819203,0.0045185247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006131472,0.00086657325,0.0019862442,0.0017827166,0.0014216832,0.005253294,0.0023380348,0.006065624,0.024910973],"category_scores_gemma":[0.027811836,0.00080752093,0.0017547439,0.0017467511,0.0012382736,0.005069708,0.0021341264,0.0154267615,0.0070344815],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002552766,0.00007858774,0.00064366794,0.00044183776,0.000034921886,0.00006797927,0.000028441073,0.00015797139,0.00008795276,0.00080597954,0.90422124,0.09317621],"study_design_scores_gemma":[0.00036716333,0.0003163459,0.0032636959,0.0030077402,0.00014100988,0.0004071685,0.00015364656,0.00045438917,0.00010478335,0.0038487527,0.9878743,0.000060931718],"about_ca_topic_score_codex":0.0051510613,"about_ca_topic_score_gemma":0.010817566,"teacher_disagreement_score":0.024910973,"about_ca_system_score_codex":0.0035011135,"about_ca_system_score_gemma":0.0041782144,"threshold_uncertainty_score":0.08333558},"labels":[],"label_agreement":null},{"id":"W4403977769","doi":"10.1007/s11523-024-01102-8","title":"Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Olaparib; Maximum tolerated dose; Open label; Refractory (planetary science); Oncology; Solid tumor; Internal medicine; Clinical trial; Cancer","score_opus":0.04736721586451495,"score_gpt":0.3932493215087382,"score_spread":0.3458821056442233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403977769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236894,0.0027048683,0.00032302394,0.0004404456,0.00012997625,0.0013825196,0.0007665547,0.00009731662,0.0017863226],"genre_scores_gemma":[0.99154973,0.0018117143,0.0010380702,0.00089782634,0.00023326195,0.0012867779,0.0017181584,0.00002451422,0.0014399862],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99966633,0.00013410259,0.000023014456,0.000067188565,0.0000363659,0.00007299596],"domain_scores_gemma":[0.9993001,0.0001304116,0.000109278924,0.000050846855,0.000034943034,0.00037445524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011921619,0.001407957,0.0020825537,0.0004311732,0.00042155036,0.0013023249,0.00084679486,0.0012081112,0.0031093825],"category_scores_gemma":[0.0007476656,0.0005472257,0.0013149413,0.0005203362,0.0008999436,0.001058017,0.000354398,0.0032027801,0.00082018017],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8169699,0.043967493,0.0047402997,0.0009252232,0.0011571612,0.00030751302,0.0002691955,0.0026437412,0.023506232,0.00023553344,0.003839758,0.10143794],"study_design_scores_gemma":[0.81554025,0.17395626,0.005356362,0.0000377924,0.00023028464,0.00026705462,0.000038508475,0.0012923676,0.0013469657,0.00020289239,0.0017067615,0.00002445153],"about_ca_topic_score_codex":0.00055914547,"about_ca_topic_score_gemma":0.0014271981,"teacher_disagreement_score":0.0031093825,"about_ca_system_score_codex":0.0008900537,"about_ca_system_score_gemma":0.0014051929,"threshold_uncertainty_score":0.010401964},"labels":[],"label_agreement":null},{"id":"W4404024879","doi":"10.1007/s11523-024-01111-7","title":"Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Victoria","funders":"AstraZeneca","keywords":"Medicine; Durvalumab; Chemoradiotherapy; Stage (stratigraphy); Oncology; Systemic therapy; Lung cancer; Internal medicine; Cancer; Pathology; Immunotherapy","score_opus":0.021619840625903716,"score_gpt":0.32708693537086064,"score_spread":0.3054670947449569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404024879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983125,0.00091791135,0.000053957316,0.000057915026,0.000014775973,0.0000044271433,0.00007769505,0.0000016706263,0.00055920694],"genre_scores_gemma":[0.9992667,0.00020467298,0.000025391455,0.000044977285,0.0000145634085,0.0000023906616,0.00014990268,0.0000010906589,0.00029027933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997726,0.00003873362,0.00001600965,0.000041817137,0.000043746608,0.00008718249],"domain_scores_gemma":[0.99952185,0.00013634963,0.00013710145,0.000025353651,0.000033527962,0.00014583732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036299767,0.0001347912,0.00052028365,0.00015185874,0.00018576025,0.00035070846,0.00018308582,0.0002733693,0.0008575329],"category_scores_gemma":[0.0010258778,0.000059850874,0.00037207117,0.00021161784,0.00015627683,0.00034640185,0.00020829479,0.0005111312,0.00017143827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028546168,0.0006228522,0.8873761,0.000054531036,0.00049036107,0.00085275836,0.00015324821,0.00047068193,0.0062779146,0.00015614412,0.00060239935,0.07439674],"study_design_scores_gemma":[0.00011037469,0.0034038983,0.9939282,0.000009025198,0.00014222461,0.0006049491,0.000085674095,0.00039692433,0.0005022341,0.00011298256,0.0006964014,0.0000070670144],"about_ca_topic_score_codex":0.0012000867,"about_ca_topic_score_gemma":0.003009213,"teacher_disagreement_score":0.0012000867,"about_ca_system_score_codex":0.00036193666,"about_ca_system_score_gemma":0.00027550152,"threshold_uncertainty_score":0.002868712},"labels":[],"label_agreement":null},{"id":"W4406352769","doi":"10.1007/s11523-024-01126-0","title":"Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Paclitaxel; Head and neck; Head and neck squamous-cell carcinoma; Basal cell; Internal medicine; Oncology; Carcinoma; Head and neck cancer; Chemotherapy; Radiation therapy; Surgery","score_opus":0.010648178780210604,"score_gpt":0.27467149228984566,"score_spread":0.26402331350963504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406352769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859329,0.011110407,0.00008000714,0.0007140139,0.000054824784,0.00006978613,0.0004109446,0.000009122662,0.0016180325],"genre_scores_gemma":[0.99489355,0.002970628,0.00013770492,0.00059682963,0.00008043932,0.00004815185,0.0006739346,0.0000031238885,0.00059569906],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959034,0.00019829236,0.000022472886,0.00004619059,0.00006765829,0.000074929696],"domain_scores_gemma":[0.99924517,0.00025427193,0.00025604147,0.000047630932,0.00007868306,0.000118257245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012971343,0.00034550263,0.00069068593,0.0002289018,0.0001770435,0.0007079786,0.00024274008,0.00039191864,0.0010990634],"category_scores_gemma":[0.0014798731,0.00014368136,0.0006471934,0.00037611835,0.00023472279,0.00058590947,0.00028435362,0.0010327863,0.00016846295],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24209303,0.003981917,0.38627416,0.0017030636,0.010959946,0.0002266739,0.0002521941,0.0020001908,0.017128145,0.0005265387,0.005673261,0.32918078],"study_design_scores_gemma":[0.02698451,0.07190132,0.8697727,0.00030762152,0.010579858,0.0006393085,0.00043115948,0.0020211295,0.005622554,0.0006371325,0.011025584,0.0000772897],"about_ca_topic_score_codex":0.00081997743,"about_ca_topic_score_gemma":0.0024789835,"teacher_disagreement_score":0.0012971343,"about_ca_system_score_codex":0.00068630587,"about_ca_system_score_gemma":0.0005299132,"threshold_uncertainty_score":0.006859958},"labels":[],"label_agreement":null},{"id":"W4406484983","doi":"10.1007/s11523-024-01123-3","title":"Bosutinib for the Treatment of CML—Using it Safely: a Podcast","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Bosutinib; Oncology; Bioinformatics; Cancer research; Dasatinib; Imatinib","score_opus":0.050757151797893,"score_gpt":0.38388280706674194,"score_spread":0.33312565526884896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406484983","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041347947,0.09748637,0.0033523056,0.10595976,0.38948336,0.0006207896,0.005119652,0.003284127,0.39055887],"genre_scores_gemma":[0.011362867,0.074159354,0.0029718757,0.04955428,0.20423354,0.0002529457,0.0036808965,0.0007320553,0.6530522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997912,0.000033195312,0.000012195604,0.00002497845,0.000102753074,0.000035758112],"domain_scores_gemma":[0.9991541,0.00018787685,0.00007960945,0.0000354259,0.00018536088,0.00035765555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048717004,0.0006643603,0.0004446194,0.0008755945,0.0006903895,0.002910736,0.00076783146,0.0019761946,0.1515176],"category_scores_gemma":[0.0016709944,0.00023001188,0.0006827283,0.00040387578,0.00032711084,0.0018601231,0.001013969,0.0033167547,0.04785627],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007113009,0.000029872708,0.00003527507,0.00009911468,0.000002502774,0.000052487514,0.000004356049,0.000020818406,0.0001794254,0.00037291666,0.955678,0.04345409],"study_design_scores_gemma":[0.000066065244,0.00007307716,0.00031980214,0.00013292299,0.0000064076207,0.00020118452,0.000013021131,0.00006872287,0.00014695972,0.0004678182,0.9984988,0.000005241302],"about_ca_topic_score_codex":0.00140714,"about_ca_topic_score_gemma":0.004321853,"teacher_disagreement_score":0.1515176,"about_ca_system_score_codex":0.0008438058,"about_ca_system_score_gemma":0.00072629127,"threshold_uncertainty_score":0.5068768},"labels":[],"label_agreement":null},{"id":"W4410569892","doi":"10.1007/s11523-025-01146-4","title":"Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation","year":2025,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Abiraterone; Prostate cancer; Oncology; PARP inhibitor; Internal medicine; Docetaxel; Cancer; BRCA mutation; Ovarian cancer; Poly ADP ribose polymerase; Androgen receptor","score_opus":0.04601313563003731,"score_gpt":0.3846335911876247,"score_spread":0.33862045555758735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410569892","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7730933,0.19800864,0.003721628,0.0038787578,0.00059959036,0.00036206946,0.002079076,0.00033347448,0.01792348],"genre_scores_gemma":[0.97501785,0.019445738,0.0012095978,0.00090344955,0.00023762682,0.000082510844,0.0010624127,0.000017165434,0.0020237283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997125,0.00012287575,0.000027353613,0.00004492086,0.000063171916,0.000029027824],"domain_scores_gemma":[0.9995542,0.00013501401,0.0001533877,0.000025828273,0.000029053748,0.00010248779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050754927,0.0002529385,0.000752428,0.00040566368,0.00012850142,0.0005356278,0.00022791463,0.00028039137,0.0022903548],"category_scores_gemma":[0.000924819,0.00010935603,0.0006754777,0.00038743162,0.00018518795,0.00031378513,0.00020377485,0.0008933724,0.0003976583],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09440894,0.0011840073,0.014261009,0.0020829043,0.002323415,0.00042761271,0.000103471415,0.0030113724,0.017367302,0.0010627533,0.0097463755,0.8540209],"study_design_scores_gemma":[0.13041426,0.2086662,0.3055866,0.003545069,0.009413038,0.018938886,0.0006949899,0.020183463,0.031770468,0.021538667,0.2488096,0.00043867133],"about_ca_topic_score_codex":0.0002776016,"about_ca_topic_score_gemma":0.0014338298,"teacher_disagreement_score":0.0022903548,"about_ca_system_score_codex":0.00027873856,"about_ca_system_score_gemma":0.0005248522,"threshold_uncertainty_score":0.007662058},"labels":[],"label_agreement":null},{"id":"W4411010011","doi":"10.1007/s11523-025-01154-4","title":"A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bayer","keywords":"Medicine; Antibody; Bay; Solid tumor; Cancer research; Oncology; Internal medicine; Immunology; Cancer","score_opus":0.010978016127561923,"score_gpt":0.37808912529642613,"score_spread":0.3671111091688642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411010011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889108,0.0041348804,0.0008710123,0.0005540426,0.00025011937,0.0017769241,0.0007886787,0.00013506059,0.0025784732],"genre_scores_gemma":[0.9850996,0.004476518,0.0018225036,0.0009244375,0.00021981011,0.0015342513,0.0021743095,0.000052360465,0.0036960805],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996561,0.00015187442,0.000012035787,0.000057867343,0.000028930759,0.00009324022],"domain_scores_gemma":[0.99956375,0.000061615276,0.00005424513,0.000039880728,0.00002657088,0.00025394582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011411156,0.0012154575,0.0021243293,0.00040651593,0.0004292056,0.00085354084,0.0007483274,0.00092669466,0.0025408815],"category_scores_gemma":[0.00059690455,0.000553631,0.0012664016,0.00048260656,0.0008052614,0.00067035755,0.00033747472,0.0031430735,0.00078787573],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50418615,0.124212496,0.00961695,0.0016165673,0.0022088399,0.00073243125,0.0006046094,0.006273162,0.11956709,0.00067058834,0.009299128,0.22101194],"study_design_scores_gemma":[0.30501828,0.6606973,0.015541176,0.000040919527,0.0007443005,0.0005591322,0.000101998536,0.002286758,0.0073887776,0.00020642093,0.0073723635,0.000042534077],"about_ca_topic_score_codex":0.0022527925,"about_ca_topic_score_gemma":0.004597893,"teacher_disagreement_score":0.0025408815,"about_ca_system_score_codex":0.0009028543,"about_ca_system_score_gemma":0.0014868234,"threshold_uncertainty_score":0.008500099},"labels":[],"label_agreement":null},{"id":"W4411055081","doi":"10.1007/s11523-025-01153-5","title":"Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Newfoundland and Labrador; AstraZeneca","keywords":"Medicine; Osimertinib; Concordance; Acquired resistance; Biopsy; Oncology; Circulating tumor DNA; Pathology; Internal medicine; Cancer; Adenocarcinoma","score_opus":0.006775695507202522,"score_gpt":0.2802244547159031,"score_spread":0.2734487592087006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411055081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999481,0.00018365042,0.00011269092,0.0000069777034,0.0000017844998,0.000004466927,0.000039848765,0.000003722808,0.00016590704],"genre_scores_gemma":[0.9996954,0.000043981243,0.00010094739,0.0000077768145,0.0000026750347,0.000003913681,0.00007381885,7.7681375e-7,0.000070809416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977213,0.000048659793,0.000034121378,0.000059268317,0.00006234352,0.000023560968],"domain_scores_gemma":[0.9992048,0.00021284756,0.00033549804,0.000036249236,0.000107527056,0.000102980455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036619013,0.00015499198,0.00020096163,0.0003808674,0.00013108428,0.00028076774,0.00015745743,0.0002805839,0.00096619944],"category_scores_gemma":[0.0012459251,0.00012738656,0.00008736201,0.000244346,0.00015511204,0.00018169681,0.00014673697,0.00021787218,0.00016385436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007830525,0.00005488242,0.97553694,0.000024677243,0.00003235063,0.0005430071,0.0000871141,0.0001333243,0.016738122,0.000012762084,0.00004817022,0.00600567],"study_design_scores_gemma":[0.000038703965,0.0011698909,0.9840349,0.000008094429,0.000050225266,0.0058117714,0.000114741466,0.00077864085,0.0075895735,0.000026898162,0.0003713014,0.0000052963806],"about_ca_topic_score_codex":0.00037122384,"about_ca_topic_score_gemma":0.000577579,"teacher_disagreement_score":0.00096619944,"about_ca_system_score_codex":0.0001732819,"about_ca_system_score_gemma":0.00009301315,"threshold_uncertainty_score":0.0032322407},"labels":[],"label_agreement":null},{"id":"W4415817417","doi":"10.1007/s11523-025-01182-0","title":"Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; Genentech; Grifols; Casen Recordati; Japanese Society of Medical Oncology; Pfizer Japan; Sociedad Española de Oncología Médica; Shionogi; Astellas Pharma; Eisai; Seagen; Lunit; Johnson and Johnson; Les Laboratories Pierre Fabre; Verily Life Sciences; BeiGene; Mirati Therapeutics; Ipsen; Five Prime Therapeutics; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Puma Biotechnology; Regeneron Pharmaceuticals; Yuhan; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Sanofi; Pfizer; Innovent Biologics; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Amgen; Mesothelioma Applied Research Foundation","keywords":"Lung cancer; Exon; Phases of clinical research; Epidermal growth factor receptor; Cell; Cancer","score_opus":0.013197917408025058,"score_gpt":0.38700755247232627,"score_spread":0.3738096350643012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415817417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392045,0.0017725684,0.0010912124,0.000074586154,0.0000636223,0.0015873904,0.000618614,0.000020517862,0.0008510836],"genre_scores_gemma":[0.99450654,0.0006236518,0.00087216235,0.00013660608,0.00005749068,0.0020466733,0.0012009441,0.000017365046,0.0005384804],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927366,0.0055216285,0.00047095786,0.00041933366,0.0005731572,0.00027837147],"domain_scores_gemma":[0.99066883,0.004629773,0.0028514853,0.000990195,0.0003085016,0.00055127474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01310331,0.00078972743,0.0016250677,0.00029003582,0.00027624692,0.0008789733,0.0006047172,0.0009412437,0.0019039171],"category_scores_gemma":[0.0075707394,0.00027975664,0.0033407677,0.00044871966,0.0005954093,0.0005603322,0.00061618676,0.0017104228,0.00015442373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9480096,0.004376732,0.014586637,0.0005327909,0.0032498862,0.00004210057,0.00010593787,0.0009867741,0.0031759397,0.000110570334,0.0003562699,0.02446674],"study_design_scores_gemma":[0.39131775,0.44199666,0.13952352,0.0002117883,0.011498609,0.00029038487,0.00013920027,0.0025282004,0.007659752,0.0007657119,0.0039764107,0.00009199621],"about_ca_topic_score_codex":0.0004685129,"about_ca_topic_score_gemma":0.0011193526,"teacher_disagreement_score":0.01310331,"about_ca_system_score_codex":0.00087444275,"about_ca_system_score_gemma":0.0011836771,"threshold_uncertainty_score":0.06929773},"labels":[],"label_agreement":null},{"id":"W4416937861","doi":"10.1007/s11523-025-01187-9","title":"Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Standard of care; MEDLINE; Patient care; Neoplasm staging; Overall survival","score_opus":0.049363425699247745,"score_gpt":0.3741072122374792,"score_spread":0.3247437865382315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416937861","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21377425,0.77614874,0.0036785738,0.00073656836,0.00097654766,0.00016289366,0.0029200881,0.000184264,0.001418017],"genre_scores_gemma":[0.9451728,0.05011958,0.0011286443,0.0010978084,0.00037740657,0.00012511954,0.0010499033,0.00008352175,0.00084511115],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9957249,0.0018006524,0.0006326113,0.0011675151,0.00032550283,0.00034874328],"domain_scores_gemma":[0.99488384,0.0028276858,0.0010774891,0.0006248012,0.00035220396,0.00023394007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055842316,0.0025483125,0.0074753356,0.0015356146,0.00060777145,0.0023453026,0.001532525,0.002008014,0.0041565713],"category_scores_gemma":[0.009608245,0.0015352872,0.037619527,0.0025790182,0.0006748649,0.0015870808,0.0013937558,0.0025829475,0.00050598034],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013940378,0.000042979595,0.033697236,0.011726656,0.9323681,0.00015890694,0.0000543228,0.00075032876,0.0007403866,0.00010215215,0.0006102184,0.0058083828],"study_design_scores_gemma":[0.0016888687,0.00049496186,0.018200127,0.000585908,0.97724575,0.000110779525,0.00004144806,0.00036493866,0.0001382054,0.00022022295,0.00087954954,0.000029350515],"about_ca_topic_score_codex":0.00631786,"about_ca_topic_score_gemma":0.01477141,"teacher_disagreement_score":0.0074753356,"about_ca_system_score_codex":0.0011881137,"about_ca_system_score_gemma":0.00095921487,"threshold_uncertainty_score":0.029532552},"labels":[],"label_agreement":null},{"id":"W4417274131","doi":"10.1007/s11523-025-01186-w","title":"Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Alberta Children's Hospital","funders":"Genentech; Roche","keywords":"Young adult; Chemotherapy; Venetoclax; Phases of clinical research; Solid tumor","score_opus":0.01157666888915094,"score_gpt":0.3287658524750596,"score_spread":0.31718918358590864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417274131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967719,0.0019246691,0.00012890648,0.00013689086,0.00003660147,0.00018346118,0.00027808058,0.000022141725,0.00051731954],"genre_scores_gemma":[0.9928838,0.003589904,0.00079644663,0.00035371224,0.00012698132,0.0003678783,0.0009947051,0.000016437172,0.00087008136],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999647,0.00020768469,0.000018245644,0.000045213175,0.000026261578,0.000055668555],"domain_scores_gemma":[0.9994931,0.00012912288,0.00010315261,0.000042479052,0.00001669938,0.00021542258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010385187,0.0007214528,0.0016432154,0.0003714543,0.00019051065,0.00075720594,0.00050806714,0.000520931,0.0012626587],"category_scores_gemma":[0.000693658,0.00030699288,0.00078429445,0.00050318136,0.00054427754,0.0005890996,0.0002324015,0.0017817765,0.0002820588],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6743121,0.05139829,0.036762804,0.0007857456,0.003287994,0.00029466866,0.00045564657,0.0027301745,0.02944272,0.000369372,0.0027122553,0.19744818],"study_design_scores_gemma":[0.33301705,0.58889884,0.06253518,0.00011034272,0.0023800877,0.00053144025,0.0002470498,0.0017778462,0.0055733137,0.00025879315,0.00462816,0.000042000167],"about_ca_topic_score_codex":0.0006926017,"about_ca_topic_score_gemma":0.0020584567,"teacher_disagreement_score":0.0016432154,"about_ca_system_score_codex":0.00048591528,"about_ca_system_score_gemma":0.00087938295,"threshold_uncertainty_score":0.00549227},"labels":[],"label_agreement":null}]}